var title_f4_14_4320="Monomeric IgA molecule";
var content_f4_14_4320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of a monomeric IgA molecule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heavy chains are shown in darker blue and brown; the light chains are shown in&nbsp;green and purple. Fab&nbsp;portions and&nbsp;Fc portion are shown in boxes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4320=[""].join("\n");
var outline_f4_14_4320=null;
var title_f4_14_4321="Strontium ranelate: International drug information";
var content_f4_14_4321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Strontium ranelate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2676360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Strontium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2523581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2523583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults (postmenopausal females): 2 g/day dissolved in water, prior to bedtime, 2 hours after eating (preferrably)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2523584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules, oral suspension: 2 g/sachet (7s, 14s, 28s, 56s, 84s, 100s) [contains phenylalanine]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10482 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4321=[""].join("\n");
var outline_f4_14_4321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676360\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523581\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523583\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821152\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523584\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10482|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4322="Patient information: Adult respiratory distress syndrome (The Basics)";
var content_f4_14_4322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33569\">",
"         Patient information: Sepsis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14225\">",
"         Patient information: Pneumonia prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Adult respiratory distress syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/adult-respiratory-distress-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H191178243\">",
"      <span class=\"h1\">",
"       What is adult respiratory distress syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Adult respiratory distress syndrome, or &ldquo;ARDS,&rdquo; is a serious lung condition. It is caused by a buildup of fluid in the lungs. A buildup of fluid in the lungs can cause problems because it can keep oxygen from getting into the blood. Then the organs in the body do not get as much oxygen as they need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178250\">",
"      <span class=\"h1\">",
"       What causes ARDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different conditions can cause ARDS, but the most common causes are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sepsis &ndash; Sepsis is a serious illness that happens when an infection affects the whole body in a certain way.",
"       </li>",
"       <li>",
"        Breathing vomit into the lungs",
"       </li>",
"       <li>",
"        A lung infection",
"       </li>",
"       <li>",
"        A severe injury to the lungs, such as from an accident",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178257\">",
"      <span class=\"h1\">",
"       What are the symptoms of ARDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of ARDS include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Breathing much faster than usual",
"       </li>",
"       <li>",
"        The fingertips and lips looking slightly blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have other symptoms, too. It depends on the cause of their ARDS. For example, a lung infection can cause a fever and cough.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178264\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, as soon as possible. Many people who get ARDS are already in a hospital. But if you are not in a hospital, you (or the person with you) should call the doctor or nurse if you have any of the symptoms above.",
"     </p>",
"     <p>",
"      If your doctor or nurse is not able to see you right away, or you can&rsquo;t reach him or her on the phone, go to the nearest emergency room.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178271\">",
"      <span class=\"h1\">",
"       Is there a test for ARDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will do an exam and a chest X-ray. He or she might also do a CT scan of your lungs. A CT scan is an imaging test that can create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      The doctor will also do other tests to see what&rsquo;s causing the ARDS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178278\">",
"      <span class=\"h1\">",
"       How is ARDS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;ARDS is treated in the hospital, usually in the intensive care unit (called &ldquo;ICU,&rdquo; for short).",
"     </p>",
"     <p>",
"      People who are having a very hard time breathing usually need a breathing tube. A breathing tube is a tube that goes down the throat and into the lungs. The other end is attached to a machine that helps with breathing.",
"     </p>",
"     <p>",
"      When the tube is in place, people are not able to eat or talk. Plus, they are usually sedated. That means the doctor has given them medicines to make them very sleepy. Once people can breathe on their own again, the doctor can take the tube out.",
"     </p>",
"     <p>",
"      If the ARDS is caused by another condition that can be treated, the doctor will treat that condition, too. For example, lung infections are treated with antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178285\">",
"      <span class=\"h1\">",
"       What problems can happen in people with ARDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different problems can happen during treatment. For example, people can get a lung infection from germs in the hospital. Or the breathing tube can harm their lungs or vocal cords (the small structures in the throat that let people speak).",
"     </p>",
"     <p>",
"      Although some people with ARDS do not get better, many do get better. But people who get better will often have long-term lung problems caused by their ARDS. They might also have thinking problems, which can happen if the brain doesn&rsquo;t get enough oxygen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H191178341\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       Patient information: Sepsis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"       Patient information: Pneumonia prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/14/4322?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17029 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4322=[""].join("\n");
var outline_f4_14_4322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178243\">",
"      What is adult respiratory distress syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178250\">",
"      What causes ARDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178257\">",
"      What are the symptoms of ARDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178264\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178271\">",
"      Is there a test for ARDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178278\">",
"      How is ARDS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178285\">",
"      What problems can happen in people with ARDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191178341\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=related_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4323="Pelvic lymphadenectomy5";
var content_f4_14_4323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissecting the proximal end of obturator nodes away from the obturator nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4323=[""].join("\n");
var outline_f4_14_4323=null;
var title_f4_14_4324="Neomycin and polymyxin B: Pediatric drug information";
var content_f4_14_4324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin and polymyxin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/7/9332?source=see_link\">",
"    see \"Neomycin and polymyxin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/5/34899?source=see_link\">",
"    see \"Neomycin and polymyxin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; G.U. Irrigant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; Irrigating Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Urinary Irrigation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Genitourinary Irrigant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/7/9332?source=see_link\">",
"      see \"Neomycin and polymyxin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Bladder irrigation: 1 mL is added to 1 L of NS with administration rate adjusted to patient's urine output; usually administered via a 3-way catheter (approximately 40 mL/hour); continuous irrigation or rinse of the urinary bladder should not exceed 10 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, irrigation: Neomycin 40 mg and polymyxin B sulfate 200,000 units per 1 mL (1 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neosporin&reg; G.U. Irrigant: Neomycin 40 mg and polymyxin sulfate B 200,000 units per 1 mL (1 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bladder irrigant: Do not inject irrigant solution; concentrated irrigant solution must be diluted in 1 liter NS before administration; connect irrigation container to the inflow lumen of a 3-way catheter to permit continuous irrigation of the urinary bladder",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store irrigant solution in the refrigerator",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term use as a continuous irrigant or rinse in the urinary bladder to prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, erythema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuromuscular blockade",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, or any component; ophthalmic use; irrigation should be avoided in patients with defects in the bladder mucosa or wall",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function, dehydrated patients, burn patients, and patients receiving a high dose for prolonged treatment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical neomycin is a contact sensitizer",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy, the manufacturer classifies neomycin and polymyxin B as pregnancy risk factor D. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, renal function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunits; polymyxin B interacts with phospholipid components in the cytoplasmic membranes of susceptible bacteria disrupting the osmotic integrity of the cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Not absorbed following topical application to intact skin; absorbed through denuded or abraded skin, peritoneum, wounds, or ulcers",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/5/34899?source=see_link\">",
"      see \"Neomycin and polymyxin B: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition worsens or if rash/irritation develops",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GU irrigant contains methylparaben",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12635 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.137.129.113-48EA216BE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4324=[""].join("\n");
var outline_f4_14_4324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200577\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048885\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048879\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200565\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200552\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048888\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048881\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200592\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048891\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048878\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048877\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299752\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200559\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413693\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048884\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048876\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048890\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048883\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048892\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/7/9332?source=related_link\">",
"      Neomycin and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/5/34899?source=related_link\">",
"      Neomycin and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4325="Atrial fibrillation 2";
var content_f4_14_4325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Lead V5 from the same patient with atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 79px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    F waves are not apparent in this lead, as the only finding suggestive of AF is the irregularly irrregular ventricular response.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4325=[""].join("\n");
var outline_f4_14_4325=null;
var title_f4_14_4326="Classification of burns";
var content_f4_14_4326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of burns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Phillip L Rice, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Dennis P Orgill, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4326/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/14/4326/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A burn is defined as a traumatic injury to the skin or other organic tissue primarily caused by thermal or other acute exposures. Burns occur when some or all of the cells in the skin or other tissues are destroyed by heat, cold, electricity, radiation, or caustic chemicals. Burns are acute wounds caused by an isolated, non-recurring insult and progress rapidly through an orderly series of healing steps [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common types of burns and their classification will be reviewed here. The clinical assessment, potential acute complications, and management of moderate and severe burns in adults and children, minor burns, and other related injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF BURNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of burn in children is from a scald injury; in adults, the most common burn occurs from a flame. The following is a list of the types of burns that may be incurred by adults and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Thermal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The depth of the burn injury is related to contact temperature, duration of contact of the external heat source, and the thickness of the skin. Because the thermal conductivity of skin is low, most thermal burns involve the epidermis and part of the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common thermal burns are associated with flames, hot liquids, hot solid objects, and steam. The depth of the burn largely determines the healing potential and the need for surgical grafting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cold exposure (frostbite)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage occurs to the skin and underlying tissues when ice crystals puncture the cells or when they create a hypertonic tissue environment. Blood flow can be interrupted, causing hemoconcentration and intravascular thrombosis with tissue hypoxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link\">",
"     \"Frostbite\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chemical burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury is caused by a wide range of caustic reactions, including alteration of pH, disruption of cellular membranes, and direct toxic effects on metabolic processes. In addition to the duration of exposure, the nature of the agent will determine injury severity. Contact with acid produces tissue coagulation, while alkaline burns generate colliquation necrosis. Systemic absorption of some chemicals is life threatening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=see_link\">",
"     \"Topical chemical burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electrical current",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical energy is transformed into thermal injury as the current passes through poorly conducting body tissues. Electroporation (injury to cell membranes) disrupts membrane potential and function. The magnitude of the injury depends on the pathway of the current, the resistance to the current flow through the tissues, and the strength and duration of the current flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic products of combustion injure airway tissues and frequently occur with flash burns from fire and steam. Hot smoke usually burns only the pharynx while steam can also burn the airway below the glottis. Many toxic chemicals produced in fires injure the lower airways with chemical burns. Carbon monoxide, which is produced from combustion, impairs cellular respiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radio frequency energy or ionizing radiation can cause damage to skin and tissues. The most common type of radiation burn is the sunburn. Depending on the photon energy, radiation can cause very deep internal burns. Radiation burns are often associated with cancer due to the ability of ionizing radiation to interact with and damage DNA. The clinical results of ionizing radiation depend on the dose, time of exposure, and type of particle that determines the depth of exposure. It is advisable for medical facilities to develop, test, and implement an action plan for emergency preparedness in advance of a potential disaster from radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link\">",
"     \"Clinical features of radiation exposure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Events that are associated with a burn may cause other injuries, such as fractures. Burns in the elderly and children may also be associated with abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H13#H13\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Burns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous burns are classified according to the depth of tissue injury: superficial or epidermal (first-degree), partial-thickness (second degree), or full thickness (third degree). Burns extending beneath the subcutaneous tissues and involving fascia, muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone are considered fourth degree (",
"    <a class=\"graphic graphic_table graphicRef61540 \" href=\"UTD.htm?2/1/2076\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Burn wounds are not usually uniform in depth and many have a mixture of deep and superficial components. A precise classification of the burn wound may be difficult and may require up to three weeks for a final determination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Thin skin, particularly on the volar surfaces of the forearms, medial thighs, perineum, and ears, sustains deeper burn injuries than suggested by initial appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/5\">",
"     5",
"    </a>",
"    ]. It is best to assume there are no shallow burns in these areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/6\">",
"     6",
"    </a>",
"    ]. Children under the age of five and adults over the age of 55 are also more susceptible to deeper burns because of thinner skin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate burn wound care may necessitate multiple treatment modalities for different parts of a burn wound depending on the burn depth of each injured part.",
"   </p>",
"   <p>",
"    In 2009, the American Burn Association (ABA) published an educational resource that reviewed the classification and management of the burn wound. The classification system below is largely in agreement with the on-line ABA publication (",
"    <a class=\"external\" href=\"file://www.ameriburn.org/\">",
"     www.ameriburn.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Burn depth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional classification of burns as first, second, third, or fourth degree was replaced by a system reflecting the need for surgical intervention. Current designations of burn depth are superficial, superficial partial-thickness, deep partial-thickness, and full-thickness (",
"    <a class=\"graphic graphic_table graphicRef61540 \" href=\"UTD.htm?2/1/2076\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73309 \" href=\"UTD.htm?24/50/25381\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/4\">",
"     4",
"    </a>",
"    ]. The term fourth degree is still used to describe the most severe burns, burns that extend into the muscle, bone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Superficial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial or epidermal burns involve only the epidermal layer of skin. They do not blister but are painful, dry, red, and blanch with pressure (",
"    <a class=\"graphic graphic_picture graphicRef55928 \" href=\"UTD.htm?28/10/28846\">",
"     picture 1",
"    </a>",
"    ). Over the next two to three days the pain and erythema subside, and by about day four, the injured epithelium peels away from the newly healed epidermis. Such injuries are generally healed in six days without scarring. This process is commonly seen with sunburns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Partial-thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial thickness burns involve the epidermis and portions of the dermis. They are characterized as either superficial or deep.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial - These burns characteristically form blisters within 24 hours between the epidermis and dermis. They are painful, red, and weeping, and blanch with pressure (",
"      <a class=\"graphic graphic_picture graphicRef75398 \" href=\"UTD.htm?20/51/21296\">",
"       picture 2",
"      </a>",
"      ). Burns that initially appear to be only epidermal in depth may be determined to be partial-thickness 12 to 24 hours later. These burns generally heal in 7 to 21 days; scarring is unusual, although pigment changes may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A layer of fibrinous exudates and necrotic debris may accumulate on the surface, which may predispose the burn wound to heavy bacterial colonization and delayed healing. These burns typically heal without functional impairment or hypertrophic scarring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep - These burns extend into the deeper dermis and are characteristically different from superficial partial-thickness burns. Deep burns damage hair follicles and glandular tissue. They are painful to pressure only, almost always blister (easily unroofed), are wet or waxy dry, and have variable mottled colorization from patchy cheesy white to red (",
"      <a class=\"graphic graphic_picture graphicRef57851 \" href=\"UTD.htm?16/33/16912\">",
"       picture 3",
"      </a>",
"      ). They do not blanch with pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If infection is prevented and wounds are allowed to heal spontaneously without grafting, they will heal in three to nine weeks. These burns invariably cause hypertrophic scarring. If they involve a joint, joint dysfunction is expected even with aggressive physical therapy. A deep partial-thickness burn that fails to heal in three weeks is functionally and cosmetically equivalent to a full thickness burn. Differentiation from full-thickness burns is often difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Full-thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;These burns extend through and destroy all layers of the dermis and often injure the underlying subcutaneous tissue. Burn eschar, the dead and denatured dermis, is usually intact. The eschar can compromise the viability of a limb or torso if circumferential.",
"   </p>",
"   <p>",
"    Full thickness burns are usually anesthetic or hypoesthetic. Skin appearance can vary from waxy white to leathery gray to charred and black. The skin is dry and inelastic and does not blanch with pressure (",
"    <a class=\"graphic graphic_picture graphicRef61036 \" href=\"UTD.htm?3/19/3376\">",
"     picture 4",
"    </a>",
"    ). Hairs can easily be pulled from hair follicles. Vesicles and blisters do not develop.",
"   </p>",
"   <p>",
"    Pale full-thickness burns may simulate normal skin except that the skin does not blanch with pressure. Features that differentiate partial-thickness from full-thickness burns may take some time to develop.",
"   </p>",
"   <p>",
"    The eschar eventually separates from the underlying tissue and reveals an unhealed bed of granulation tissue. Without surgery, these wounds heal by wound contracture with epithelialization around the wound edges. Scarring is severe with contractures; complete spontaneous healing is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fourth degree burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fourth degree burns are deep and potentially life-threatening injuries that extend through the skin into underlying tissues such as fascia, muscle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PERCENT BODY SURFACE AREA ESTIMATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough and accurate estimation of burn size is essential to guide therapy and to determine when to transfer a patient to a burn center.",
"   </p>",
"   <p>",
"    In several observational reports comparing the estimation of burn size at the referring hospital with the estimation at the receiving burn center, the size of larger burns was underestimated. This resulted in underresuscitation at the referring hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Early transfer to a burn center should be arranged when injuries meet the criteria for major burns (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H4#H4\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Initial interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of burns is expressed as the total percentage of body surface area (TBSA). Superficial burns are not included in the TBSA burn assessment. The location of partial-thickness and full-thickness burned areas are recorded on a burn diagram (",
"    <a class=\"graphic graphic_figure graphicRef71190 \" href=\"UTD.htm?42/35/43575\">",
"     figure 2",
"    </a>",
"    ). Burns with an appearance compatible with either deep partial-thickness or full-thickness are presumed to be full-thickness until accurate differentiation is possible.",
"   </p>",
"   <p>",
"    The two commonly used methods of assessing TBSA in adults are the Lund-Browder chart and \"Rule of Nines,\" whereas in children, the Lund-Browder chart is the recommended method because it takes into account the relative percentage of body surface area affected by growth.",
"   </p>",
"   <p>",
"    When the burn is irregular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patchy, the palm method may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lund-Browder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lund-Browder chart is the most accurate method for estimating TBSA for both adults and children. It takes into account the relative percentage of body surface area affected by growth (",
"    <a class=\"graphic graphic_figure graphicRef71190 \" href=\"UTD.htm?42/35/43575\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. Children have proportionally larger heads and smaller lower extremities, so the percentage BSA is more accurately estimated using the Lund-Browder chart (",
"    <a class=\"graphic graphic_table graphicRef50237 \" href=\"UTD.htm?32/9/32924\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71190 \" href=\"UTD.htm?42/35/43575\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rule of Nines",
"    </span>",
"    &nbsp;&mdash;&nbsp;For adult assessment, the most expeditious method to estimate TBSA in adults is the \"Rule of Nines\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Each leg represents 18 percent TBSA",
"     </li>",
"     <li>",
"      Each arm represents 9 percent TBSA",
"     </li>",
"     <li>",
"      The anterior and posterior trunk each represent 18 percent TBSA",
"     </li>",
"     <li>",
"      The head represents 9 percent TBSA",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Palm method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small or patchy burns can be approximated by using the surface area of the patient's palm. The palm of the patient's hand, excluding the fingers, is approximately 0.5 percent of total body surface area and the entire palmar surface including fingers is 1 percent in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H583379466\">",
"    <span class=\"h2\">",
"     Anterior chest wall burns in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percent of total body surface area (TBSA) burned may be underestimated in women with burns of the anterior trunk and large breasts. A table based on the cup size of a brassiere is intended to complement the Lund and Browder chart for burn estimation in adults. In a review of 60 volunteers to determine the difference in TBSA of the anterior trunk between men and women, large breasted women (cup size D and greater) were found to have a significantly greater amount of TBSA on the anterior chest in comparison to men (16 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4326/abstract/17\">",
"     17",
"    </a>",
"    ]. This additional TBSA is concentrated on the pectoral region, and represents 10 percent of TBSA as compared to 5 percent for men and 7 percent for women with smaller breasts. There was an equal distribution of anterior and posterior trunk TBSA in men, but a 1.6 to 1 ratio in large breasted women. For every increase in cup size, the TBSA of a woman&rsquo;s anterior trunk increases by a factor of 0.1, relative to the posterior trunk (",
"    <a class=\"graphic graphic_figure graphicRef59647 \" href=\"UTD.htm?41/52/42829\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Percent body surface area estimates'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A burn is defined as a traumatic injury to the skin or other organic tissue primarily caused by thermal or other acute exposures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous burns are classified according to the depth of tissue injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough estimation of burn size is essential to guide therapy. The extent of burns is expressed as the total percentage of body surface area (TBSA). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Percent body surface area estimates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimation of percent total body surface area includes partial-thickness, full-thickness, and fourth degree burns. Superficial burns are not included in the TBSA burn assessment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Percent body surface area estimates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most accurate method of assessment of TBSA burn in children and adults is the Lund-Browder chart. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Lund-Browder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Burn Association White Paper. Surgical management of the burn wound and use of skin substitutes. Copyright 2009. www.ameriburn.or (Accessed on January 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/2\">",
"      Orgill DP, Solari MG, Barlow MS, O'Connor NE. A finite-element model predicts thermal damage in cutaneous contact burns. J Burn Care Rehabil 1998; 19:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/3\">",
"      Wolbarst AB, Wiley AL Jr, Nemhauser JB, et al. Medical response to a major radiologic emergency: a primer for medical and public health practitioners. Radiology 2010; 254:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/4\">",
"      Mertens DM, Jenkins ME, Warden GD. Outpatient burn management. Nurs Clin North Am 1997; 32:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/5\">",
"      Baxter CR. Management of burn wounds. Dermatol Clin 1993; 11:709.",
"     </a>",
"    </li>",
"    <li>",
"     Pham, TN, Girban, NS, Heimbach, DM. Evaluation of the burn wound: Management decisions. In: Total Burn Care, 3rd edition, Herndon, D (Eds), Saunders Elsevier, Philadelphia 2007. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/7\">",
"      Collis N, Smith G, Fenton OM. Accuracy of burn size estimation and subsequent fluid resuscitation prior to arrival at the Yorkshire Regional Burns Unit. A three year retrospective study. Burns 1999; 25:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/8\">",
"      Hagstrom M, Wirth GA, Evans GR, Ikeda CJ. A review of emergency department fluid resuscitation of burn patients transferred to a regional, verified burn center. Ann Plast Surg 2003; 51:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/9\">",
"      Freiburg C, Igneri P, Sartorelli K, Rogers F. Effects of differences in percent total body surface area estimation on fluid resuscitation of transferred burn patients. J Burn Care Res 2007; 28:42.",
"     </a>",
"    </li>",
"    <li>",
"     Woodson, LC, Sherwood, ER, Aarsland, A, et, al. Anesthesia for burned patients. In: Total Burn Care, 3rd edition, Herndon, DN (Eds), Saunders Elsevier, Philadelphia 2007. p.196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/11\">",
"      Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obstet 1944; 79:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/12\">",
"      Monafo WW. Initial management of burns. N Engl J Med 1996; 335:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/13\">",
"      Wachtel TL, Berry CC, Wachtel EE, Frank HA. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns 2000; 26:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/14\">",
"      Perry RJ, Moore CA, Morgan BD, Plummer DL. Determining the approximate area of a burn: an inconsistency investigated and re-evaluated. BMJ 1996; 312:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/15\">",
"      Sheridan RL, Petras L, Basha G, et al. Planimetry study of the percent of body surface represented by the hand and palm: sizing irregular burns is more accurately done with the palm. J Burn Care Rehabil 1995; 16:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/16\">",
"      Nagel TR, Schunk JE. Using the hand to estimate the surface area of a burn in children. Pediatr Emerg Care 1997; 13:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4326/abstract/17\">",
"      Hidvegi N, Nduka C, Myers S, Dziewulski P. Estimation of breast burn size. Plast Reconstr Surg 2004; 113:1591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 819 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-189.41.172.26-9D38EAC1B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4326=[""].join("\n");
var outline_f4_14_4326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF BURNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Thermal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cold exposure (frostbite)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chemical burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electrical current",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inhalation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Burn depth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Superficial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Partial-thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Full-thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fourth degree burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PERCENT BODY SURFACE AREA ESTIMATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lund-Browder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rule of Nines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Palm method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H583379466\">",
"      Anterior chest wall burns in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/819|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/50/25381\" title=\"figure 1\">",
"      Burn class depth skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/35/43575\" title=\"figure 2\">",
"      Burn class adult child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/52/42829\" title=\"figure 3\">",
"      Breast burns TBSA burn anterior and posterior trunk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/819|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/10/28846\" title=\"picture 1\">",
"      Superficial burn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/51/21296\" title=\"picture 2\">",
"      Superficial partial thick burn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/33/16912\" title=\"picture 3\">",
"      Deep partial thickness burn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/19/3376\" title=\"picture 4\">",
"      Full thickness burn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/1/2076\" title=\"table 1\">",
"      Burn class depth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2268\" title=\"table 2\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/9/32924\" title=\"table 3\">",
"      Burn class chart",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=related_link\">",
"      Clinical features of radiation exposure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=related_link\">",
"      Topical chemical burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4327="WHO head circumference for age boys 0 to 24 months";
var content_f4_14_4327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58632%7EPEDS%2F74503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58632%7EPEDS%2F74503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Head circumference-for-age percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Head circumference-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4327=[""].join("\n");
var outline_f4_14_4327=null;
var title_f4_14_4328="Psychosocial treatment for adolescent depression";
var content_f4_14_4328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychosocial treatment for adolescent depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4328/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4328/contributors\">",
"     Liza Bonin, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4328/contributors\">",
"     C Scott Moreland, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4328/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4328/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/14/4328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 19, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial interventions teach patients and their families to understand themselves and the nature of depression, as well as to effectively manage relationships and life stressors associated with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/1\">",
"     1",
"    </a>",
"    ]. Psychosocial interventions also help the patient to cope with depressive symptoms, improve social and self-management skills, and increase self-confidence.",
"   </p>",
"   <p>",
"    Psychosocial treatments include, but are not limited to, cognitive-behavioral therapy (CBT), interpersonal therapy for adolescents (IPT-A), family therapy, dynamic therapy, group therapy, and supportive therapy. Among these, only CBT and IPT-A have been shown to be efficacious in controlled research within a delineated population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The psychosocial interventions for the treatment of adolescent depression will be discussed below. An overview of treatment for adolescent depression and pharmacologic treatments for adolescent depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=see_link\">",
"     \"Overview of treatment for adolescent depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of the psychosocial treatment strategy employed, the following considerations are important for effective intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once adolescent depression has been identified, psychosocial treatment begins with a systematic assessment of the different domains that will be targets for intervention (ie, cognitive, behavioral, emotional, and interpersonal) using multiple methods and informants.",
"     </li>",
"     <li>",
"      Evaluation for comorbid disorders is critical; comorbidity is the rule rather than the exception for adolescents. Comorbid conditions often warrant adjunct psychosocial, educational, or medical intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H4#H4\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Comorbidity'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjunct psychosocial therapies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Although depression generally is conceptualized as an individual disorder, a multitude of interpersonal problems or maladaptive interaction patterns contribute to its development and maintenance. These difficulties need to be addressed in context of the intervention (eg, social problem solving), and possibly require adjunct therapies, such as family or group therapy, if the interpersonal problems do not respond to depression-specific individual therapy intervention. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjunct psychosocial therapies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The adolescent's relationship with his or her therapist is a central therapeutic factor. Without a solid therapeutic working alliance, the effectiveness of psychosocial intervention will be limited. The working alliance is based on trust, genuineness, respect, understanding, and a norm of collaboration.",
"     </li>",
"     <li>",
"      A solid working alliance with the adolescent's parents is key to regular therapy attendance (ie, fewer cancellations and no-shows) and greater therapist concurrence with termination of treatment.",
"     </li>",
"     <li>",
"      The early stages of treatment need to include instillation of hope that intervention can be effective, depression can remit, and problems are not insurmountable. Instilling hope activates the adolescent's motivation to engage in treatment. Moreover, it is important to attend to hopelessness early in the intervention because hopelessness predicts dropout and poor response to treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clearly identifying specific psychological and psychosocial processes that are maintaining an adolescent's depression and using these data in clinical decision making is central to providing individualized and effective care [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/4\">",
"       4",
"      </a>",
"      ]. This often includes addressing adolescent-specific issues such as parent-adolescent conflict, separation and individuation concerns, peer pressure, sexual identity, dating, substance use, and school performance.",
"     </li>",
"     <li>",
"      Effective treatment requires that clinicians obtain ongoing feedback regarding level of symptoms through systematic monitoring of depressed mood and associated symptoms. This objective can be achieved by having adolescents self-monitor using symptom-focused self-report forms that are based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for depression (",
"      <a class=\"graphic graphic_table graphicRef70455 \" href=\"UTD.htm?22/48/23309\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intervention should include psychoeducation regarding relapse prevention and availability of \"booster sessions\" (maintenance therapy) as needed.",
"     </li>",
"     <li>",
"      CBT and IPT-A approaches are not suitable for all depressed adolescents. Both treatments are active therapies, and motivation on the part of the adolescent is required for effective implementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Choosing a therapist",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an adolescent presents with clinically significant depressive symptoms, individual therapy (CBT or IPT-A) typically is the psychosocial treatment of choice. Group therapy generally is not indicated unless the group is a depression-specific CBT group. CBT and IPT-A typically are pursued on an outpatient basis and provided by various licensed mental health clinicians (eg, psychologists, psychiatrists, clinical social workers, and professional counselors).",
"   </p>",
"   <p>",
"    The first steps in choosing a therapist involve determining:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The therapist's approach to treatment",
"     </li>",
"     <li>",
"      Training in evidence-based approaches",
"     </li>",
"     <li>",
"      Experience treating depression in adolescents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most psychologists receive formal training in CBT; however, many therapists outside of psychology have training in CBT as well. Training in IPT-A is less common than CBT. One way to find a cognitive-behaviorally oriented therapist is to consult the Association for Behavioral and Cognitive Therapies (ABCT). Another important consideration when choosing a therapist is whether family members are included in the treatment. Treatment typically is more effective when family members (particularly parents) are included to support and maintain treatment gains. Below are some examples of useful questions to ask of the therapist:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is your approach to treatment?",
"     </li>",
"     <li>",
"      What type of training or experience do you have treating depression in adolescents?",
"     </li>",
"     <li>",
"      What type of training or experience do you have with CBT (or IPT-A)?",
"     </li>",
"     <li>",
"      Are family members included in some aspects of the treatment? How?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment planning should be collaborative with the adolescent. His or her family should be well informed and involved in the planning process. The treatment plan should indicate the frequency of sessions based on the severity of symptoms, the age and developmental status of the patient, the degree of current exposure to negative life events, and other clinical factors. Multiple sessions per week may be needed during the acute treatment phase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the plan should recommend involvement of parents in treatment and other interventions directed at the child's environment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COGNITIVE-BEHAVIORAL THERAPY (CBT)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Description",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is a brief psychosocial intervention that is comprised of a variety of therapeutic approaches (",
"    <a class=\"graphic graphic_form graphicRef73776 \" href=\"UTD.htm?24/42/25260\">",
"     form 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_form graphicRef53738 \" href=\"UTD.htm?5/1/5150\">",
"     form 2",
"    </a>",
"    ). All of the approaches share the basic assumption that therapeutic change can be effected by targeting changes in thoughts (beliefs and attitudes) and behaviors that contribute to emotional distress [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/6\">",
"     6",
"    </a>",
"    ]. Some forms give more emphasis to thoughts or cognitions, whereas others emphasize behaviors.",
"   </p>",
"   <p>",
"    The cognitive-focused tradition of CBT is based on the premise that individuals who are depressed have a distorted view of themselves, the world, and the future [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/1\">",
"     1",
"    </a>",
"    ]. These cognitive distortions play an important role in depression and can be counteracted through CBT. Examples of cognitive targets for change include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distorted thoughts about specific events, such as all-or-none thinking or perfectionism",
"     </li>",
"     <li>",
"      Maladaptive global perceptions about oneself, the world, and future",
"     </li>",
"     <li>",
"      Cognitive deficits such as poor social problem solving",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Behavioral activation and improvement in relationships is often \"half the battle\" in helping adolescents to resume a productive developmental trajectory. Behavioral targets often involve modifying complications of depression that maintain and worsen symptoms. Examples of behavioral targets include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Addressing poor sleep hygiene",
"     </li>",
"     <li>",
"      Engagement in physical exercise",
"     </li>",
"     <li>",
"      Increasing behaviors that provide pleasure",
"     </li>",
"     <li>",
"      Increasing behaviors that provide a sense of mastery",
"     </li>",
"     <li>",
"      Improving social skills and social involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the cognitive-focused and the behavior-focused approaches have empirical support for efficacy in treatment of depressed adolescents, as discussed below. Regardless of emphasis, the efficacious forms of CBT for depression in adolescents share the following methods or treatment components [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing involvement in pleasurable, mood-enhancing activities",
"     </li>",
"     <li>",
"      Increasing quantity and improving quality of social interactions",
"     </li>",
"     <li>",
"      Improving conflict resolution and social problem-solving skills",
"     </li>",
"     <li>",
"      Reducing physiological tension",
"     </li>",
"     <li>",
"      Modifying or restructuring depressogenic thoughts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Studies of CBT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of CBT in the treatment of adolescent depression has been studied in controlled trials comparing it with other psychosocial therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ], drug therapy (alone or in combination with CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/11\">",
"     11",
"    </a>",
"    ], pill placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/11\">",
"     11",
"    </a>",
"    ], no therapy (ie, waitlist or treatment-as-usual) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and in meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/6,14-16\">",
"     6,14-16",
"    </a>",
"    ]. The lack of standardized entry criteria, outcome measures, and comparison groups makes it difficult to compare the results between studies. The results of the studies vary, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one clinical trial, 107 adolescents with major depressive disorder (MDD) were randomly assigned to one of three psychosocial treatments: CBT, systemic behavioral family therapy, or nondirective supportive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/9\">",
"       9",
"      </a>",
"      ]. More adolescents in the CBT group achieved remission at the end of acute treatment (60 versus approximately 40 percent for family and supportive therapy). In a separate analysis, factors predictive of poor outcome were evaluated. These included clinical referral (versus response to an advertisement), hopelessness, comorbid anxiety, cognitive distortion, and maternal depressive symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another clinical trial, 53 children and adolescents with depressive disorders were randomly assigned to five to eight sessions of CBT or relaxation training [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/10\">",
"       10",
"      </a>",
"      ]. CBT showed a clear advantage on measures of depression and overall outcome in most patients, but not for those with comorbid anxiety or conduct symptoms. At follow-up, the differences between groups were reduced because of a high relapse rate in the CBT group and continued improvement in the relaxation group.",
"     </li>",
"     <li>",
"      In the Treatment for Adolescent with Depression Study (TADS), adolescents with MDD were assigned randomly to four treatment groups: CBT alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      alone, combination CBT and fluoxetine, and pill placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/11\">",
"       11",
"      </a>",
"      ]. Combination therapy with CBT and fluoxetine was most effective during the acute phase (response rate of 71 percent). The response rate to CBT monotherapy was 43 percent, which was not statistically different from in the pill placebo group (35 percent).",
"      <br/>",
"      <br/>",
"      The response rate of CBT monotherapy was lower in TADS than in other studies of CBT. However, in the second phase of TADS (which extended to 36 weeks), the response rate for CBT increased to 65 percent at week 18 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/17\">",
"       17",
"      </a>",
"      ]. This supports the hypothesis that the increased severity of illness in TADS patients compared to those in other studies delayed the onset of benefit for CBT relative to other therapies. This is consistent with results of trials in adult patients in which the comparative of strength of CBT is greater during follow-up than acute treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although CBT was less efficacious than fluoxetine or combination therapy during the acute phase of treatment, CBT appeared to protect against suicidal ideation, and, when combined with fluoxetine, to protect against suicidal ideation and other harm-related adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/11,17\">",
"       11,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Treatment of Resistant Depression In Adolescents (TORDIA) trial, 344 adolescents with MDD unresponsive to treatment with SSRI were randomly assigned to treatment with another SSRI, another SSRI and CBT,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      , or venlafaxine and CBT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/19\">",
"       19",
"      </a>",
"      ]. The response rate was greater in patients whose switch included CBT than in those whose who underwent medication switch alone (55 percent [95% CI 47-62 percent] versus 41 percent [95% CI 33-48 percent]).",
"     </li>",
"     <li>",
"      One meta-analysis of six controlled studies comparing CBT for adolescent depression (diagnosed with standardized criteria) to inactive interventions found CBT to be efficacious, with a higher remission rate (62 versus 36 percent, pooled odds ratio 3.2, 95% CI 1.9-5.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/14\">",
"       14",
"      </a>",
"      ]. Another meta-analysis that included studies of adolescent with depressive symptoms as well as those with MDD also found CBT to be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effects of comorbidity on benefit from CBT in a group setting were evaluated in a separate analysis of two previously reported studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/13,20\">",
"       13,20",
"      </a>",
"      ], and included 60 depressed adolescents with comorbid conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/21\">",
"       21",
"      </a>",
"      ]. Overall lifetime comorbidity was unrelated to recovery. However, comorbid anxiety was associated with a greater decrease in depression scores after treatment and comorbid substance",
"      <span class=\"nowrap\">",
"       abuse/dependence",
"      </span>",
"      was associated with slower time to recovery. Posttreatment recurrence was more likely in patients with comorbid attention-deficit and disruptive disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Continuation or maintenance phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are fewer controlled trials of CBT during the continuation or maintenance phase than in the acute phase of treatment for adolescent depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated whether continuation of monthly CBT for six months after remission could prevent relapse in 17 adolescent patients with MDD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/12\">",
"       12",
"      </a>",
"      ]. Compared with 12 historic controls who had no further treatment after remission, those who continued with CBT had a statistically significant lower cumulative risk of relapse (20 versus 50 percent).",
"     </li>",
"     <li>",
"      Another study compared assessment with \"booster\" sessions of CBT every four months, assessment alone every four months, and assessment every 12 months for a 24-month period among adolescents who had received an eight-week course of CBT for depression [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/13\">",
"       13",
"      </a>",
"      ]. Although booster sessions did not reduce the rate of recurrence during the follow-up period, they appeared to hasten recovery among adolescents who remained depressed after the initial eight weeks of CBT.",
"     </li>",
"     <li>",
"      In a third study, 46 children and adolescents (age 11 to 18 years) who had responded to 12 weeks of treatment with pharmacotherapy were randomly assigned to receive six months of continuation therapy with pharmacotherapy or pharmacotherapy plus CBT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/22\">",
"       22",
"      </a>",
"      ]. The risk of relapse was reduced among the patients receiving combined pharmacotherapy and CBT (hazard ration 8.8 (95% CI 1.01-76.89)).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less effective than combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/11\">",
"     11",
"    </a>",
"    ], CBT monotherapy is more effective than other psychosocial interventions in reducing symptoms and inducing remission. The rates of remission range from 50 to 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/23\">",
"     23",
"    </a>",
"    ]. CBT also appears to be beneficial in preventing relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/12,22\">",
"     12,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of poor outcome with psychosocial therapies include clinical referral (versus response to an advertisement), parental psychopathology, family disturbance, high level of cognitive distortion, and hopelessness. In addition, adolescents with comorbid disorders (eg, anxiety, disruptive behavior, substance",
"    <span class=\"nowrap\">",
"     abuse/dependence)",
"    </span>",
"    may have worse outcomes (eg, slower recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/21\">",
"     21",
"    </a>",
"    ]) than those who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/3\">",
"     3",
"    </a>",
"    ] . Nonetheless, patients with comorbidity appear to benefit from depression-specific CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/21\">",
"     21",
"    </a>",
"    ], and in these patients, CBT is more effective than other psychosocial treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of CBT for depression have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Youth with marked cognitive or language deficits or disabilities may have difficulty benefiting from CBT because of limited understanding and thus limited engagement in the treatment. If significant psychosocial issues are present in an adolescent with such disabilities, family therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parent education and guidance is more likely to be productive than CBT.",
"   </p>",
"   <p>",
"    When an adolescent is resistant to psychosocial treatment, the initial portion of treatment focuses on building rapport and working to find common objectives to use as a basis for development of a working alliance. If motivation to actively engage in treatment is not present (and can not be instilled early in the course of intervention), treatment effectiveness will be limited and thus is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Typical course of CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT intervention typically is administered weekly (and sometimes biweekly). Depending upon the protocol, acute or active treatment ranges from 8 to 18 weeks, with most treatments providing 12 to 15 therapy sessions. Treatment typically includes homework assignments (eg, self-monitoring, activity scheduling). Throughout treatment, depressive symptoms and mastery of CBT skills are monitored by the therapist. Most treatment protocols provide for a continuation phase (eg, monthly booster treatment sessions) to maintain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extend gains. The latter portion of treatment involves psychoeducation and planning for",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    prevention. Discontinuation typically is based on resolution of depressive symptoms (based on standardized rating scales) and the patient's sense of efficacy to maintain gains. Once CBT is discontinued, the patient, family, and primary care clinician should monitor for recurrence of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INTERPERSONAL PSYCHOTHERAPY FOR ADOLESCENTS (IPT-A)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Description",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal psychotherapy for adolescents (IPT-A) is a brief psychosocial therapy that is an adaptation of interpersonal therapy (IPT) developed and tested for depressed adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. According to this treatment model, there are many possible pathways into depression, but independent of the cause, depression is associated with relationship disruptions. Thus, IPT-A focuses on current relationship problems associated with the adolescent's depression.",
"   </p>",
"   <p>",
"    The initial phase of treatment includes exploring the adolescent's relationships by conducting a relationship inventory to identify problem areas that will be the focus of treatment. Typical foci of treatment include grief reactions, interpersonal conflicts (such as parent-child disputes or peer conflicts), role disputes, adjustments and transitions, interpersonal deficits, and adjustments related to single parent families in the context of divorce, separation, incarceration, death, etc.",
"   </p>",
"   <p>",
"    The IPT-A approach takes into account developmentally relevant issues for adolescents such as establishing autonomy, negotiating romantic relationships, sexual orientation, managing parent-adolescent tensions, and coping with peer pressures. Through weekly individual intervention, the therapist helps the adolescent identify specific strategies to successfully manage interpersonal difficulties related to his or her depression. Typical IPT-A techniques include promoting effective expression of affect, clarifying and reframing expectations for relationships, communication analysis, social problem solving, and role playing of effective methods of interaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Studies of IPT-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although IPT-A is not as well studied as CBT, it is established as an evidence-based treatment for depression in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/7\">",
"     7",
"    </a>",
"    ]. Three of the supporting studies are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled clinical trial, 48 clinic-referred adolescents (aged 12 to 18 years) with MDD were assigned randomly to either weekly IPT-A or clinical monitoring for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/28\">",
"       28",
"      </a>",
"      ]. Outcomes, including symptoms of depression, social functioning, and social problem-solving skills were measured by an independent evaluator who was unaware of the treatment assignment; 32 patients completed the protocol, 21 in the IPT-A group, but only 11 in the control group. Among the control group patients who did not complete the protocol, four patients were removed for suicidality, one for psychotic symptoms, one for school refusal, four for noncompliance, and three withdrawals were patient initiated. Compared with those in the control group, those in the IPT-A group reported decrease in depressive symptoms and greater improvement in social functioning and problem-solving skills. In the intention to treat analysis, more patients in the IPT-A group met recovery criteria (Hamilton Rating Scale for Depression score &le;6) at week 12 (18 versus 11 of 24).",
"     </li>",
"     <li>",
"      In another controlled trial, 63 adolescents referred to school-based mental health clinics in New York City for depression were randomly assigned to receive IPT-A or treatment as usual for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/29\">",
"       29",
"      </a>",
"      ]. Those treated with IPT-A showed greater symptom reduction, improvement in overall functioning, and better overall social functioning than those who received treatment as usual.",
"     </li>",
"     <li>",
"      In another study, 71 Puerto Rican adolescents with depression were assigned randomly to one of three groups: IPT, CBT, or placement on a wait list for treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/30\">",
"       30",
"      </a>",
"      ]. Depressive symptoms were reduced in the first two groups compared with the third. After treatment, more adolescents in the IPT group were able to function socially than in the CBT group (82 versus 59 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given IPT-A's time-limited nature, it is not recommended for adolescents with a long-standing history of severe interpersonal dysfunction (eg, personality disorders); rather, it is well suited to those adolescents who have an identifiable interpersonal event that precipitated or clearly exacerbated a depressive episode [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/31\">",
"     31",
"    </a>",
"    ]. Similar to CBT, IPT-A is not recommended for youth with markedly limited cognitive or language skills or those who will not engage in treatment. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Typical course of IPT-A'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Typical course of IPT-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical course of IPT-A consists of 12 weekly 45-minute sessions (with additional weekly telephone contacts during the first month). Throughout treatment, depressive symptoms and current interpersonal functioning are monitored. The latter portion of treatment involves psychoeducation and planning for",
"    <span class=\"nowrap\">",
"     relapse/recurrence",
"    </span>",
"    prevention. Monthly follow-up or maintenance often is provided as indicated based upon the adolescent's management of his or her mood and relationships. Once IPT-A is discontinued, the patient, family, and primary care clinician should monitor for recurrence of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADJUNCT PSYCHOSOCIAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunct psychosocial interventions that may be warranted depending upon the adolescent's circumstances and functioning include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family therapy",
"     </li>",
"     <li>",
"      Substance abuse treatment",
"     </li>",
"     <li>",
"      Eating disorder treatment",
"     </li>",
"     <li>",
"      Group therapy",
"     </li>",
"     <li>",
"      Dynamic or long-term psychotherapy approaches",
"     </li>",
"     <li>",
"      Supportive therapy or support groups",
"     </li>",
"     <li>",
"      Psychoeducational interventions and modifications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These interventions have not been proven to address the core symptoms of adolescent depression. Nonetheless, they may be indicated depending upon contextual, intrapersonal, or individual factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/32\">",
"     32",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate intervention for a depressed adolescent who presents with a learning disability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      attention deficit hyperactivity disorder (ADHD) that has not been effectively managed would involve: an evaluation of the nature of learning disability or deficits; establishment of appropriate expectations; implementation of educational supports and modifications in school system; and, if warranted by nature of disability (eg, ADHD), medication management. Addressing the adolescent's disability permits more effective psychosocial and psychoeducational functioning, thereby reducing a core source of the adolescent's stress and demoralization. The evaluation and management of learning disabilities and ADHD are discussed separately. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Appropriate intervention for a depressed adolescent who has comorbid diagnoses, such as anxiety or substance abuse, requires simultaneous treatment of the comorbid disorder.",
"     </li>",
"     <li>",
"      When depression is complicated by suicidality, a multi-modal approach is warranted once immediate safety concerns have been addressed. Such a multi-modal intervention would likely include family-based interventions that would address suicide risk and environmental stressors in addition to individual therapy to address depressive symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"       \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"       \"Evaluation and management of suicidal behavior in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial treatments are an important component of the treatment of depression in adolescents. Among the psychosocial treatments, only cognitive-behavioral therapy (CBT) and interpersonal therapy for adolescents (IPT-A) have been shown to be effective in controlled trials.",
"   </p>",
"   <p>",
"    CBT is based upon the assumption that targeting changes in thoughts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behaviors can effect therapeutic change. Effective forms of CBT focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing involvement in pleasurable, mood-enhancing activities",
"     </li>",
"     <li>",
"      Increasing quantity and improving quality of social interactions",
"     </li>",
"     <li>",
"      Improving conflict resolution and social problem-solving skills",
"     </li>",
"     <li>",
"      Reducing physiological tension",
"     </li>",
"     <li>",
"      Modifying or restructuring depressogenic thoughts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the acute phase of therapy for moderate or severe depression, CBT is most effective when combined with antidepressant medication. Its role in the durability of response during the maintenance phase of therapy remains to be determined, but it appears to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4328/abstract/12,22\">",
"     12,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cognitive-behavioral therapy (CBT)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    IPT-A is based upon the assumption that, independent of the cause of depression, depression is associated with disrupted relationships. It focuses on relationship problems associated with the adolescent's depression. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Interpersonal psychotherapy for adolescents (IPT-A)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When choosing a therapist, it is important to consider the therapist's training and experience implementing evidence-based approaches with adolescents, as well as whether or not family members will be incorporated in the adolescent's treatment. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Choosing a therapist'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/1\">",
"      Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP. J Am Acad Child Adolesc Psychiatry 1998; 37:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/2\">",
"      Chambless DL, Hollon SD. Defining empirically supported therapies. J Consult Clin Psychol 1998; 66:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/3\">",
"      Brent DA, Kolko DJ, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998; 37:906.",
"     </a>",
"    </li>",
"    <li>",
"     Shirk, SR, Russell, RL. Change processes in child psychotherapy: Revitalizing treatment and research. Guilford, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/5\">",
"      Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/6\">",
"      Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 1998; 37:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/7\">",
"      Kaslow NJ, Thompson MP. Applying the criteria for empirically supported treatments to studies of psychosocial interventions for child and adolescent depression. J Clin Child Psychol 1998; 27:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/8\">",
"      Kazdin AE, Weisz JR. Identifying and developing empirically supported child and adolescent treatments. J Consult Clin Psychol 1998; 66:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/9\">",
"      Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997; 54:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/10\">",
"      Wood A, Harrington R, Moore A. Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders. J Child Psychol Psychiatry 1996; 37:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/11\">",
"      March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/12\">",
"      Kroll L, Harrington R, Jayson D, et al. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry 1996; 35:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/13\">",
"      Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry 1999; 38:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/14\">",
"      Harrington R, Whittaker J, Shoebridge P, Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998; 316:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/15\">",
"      Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull 2006; 132:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/16\">",
"      Compton SN, March JS, Brent D, et al. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. J Am Acad Child Adolesc Psychiatry 2004; 43:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/17\">",
"      March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/18\">",
"      Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/19\">",
"      Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/20\">",
"      Lewinsohn, PM, Clarke, GN, Hops, H, Andrews, J. Cognitive behavioral treatment for depressed adolescents. Behav Ther 1990; 21:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/21\">",
"      Rohde P, Clarke GN, Lewinsohn PM, et al. Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression. J Am Acad Child Adolesc Psychiatry 2001; 40:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/22\">",
"      Kennard BD, Emslie GJ, Mayes TL, et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. J Am Acad Child Adolesc Psychiatry 2008; 47:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/23\">",
"      Lewinsohn PM, Clarke GN. Psychosocial treatments for adolescent depression. Clin Psychol Rev 1999; 19:329.",
"     </a>",
"    </li>",
"    <li>",
"     Mufson, L, Moreau, D, Weissman, MM, Klerman, G. Interpersonal psychotherapy for depressed adolescents. Guilford, New York 1993.",
"    </li>",
"    <li>",
"     Klerman, GL, Weissman, MW, Rounsaville, BJ, Cheveron, ES. Interpersonal psychotherapy for depression (The Master Work Series), Jason Aronson, New York 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/26\">",
"      Moreau D, Mufson L, Weissman MM, Klerman GL. Interpersonal psychotherapy for adolescent depression: description of modification and preliminary application. J Am Acad Child Adolesc Psychiatry 1991; 30:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/27\">",
"      Mufson L, Moreau D, Weissman MM, et al. Modification of interpersonal psychotherapy with depressed adolescents (IPT-A): phase I and II studies. J Am Acad Child Adolesc Psychiatry 1994; 33:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/28\">",
"      Mufson L, Weissman MM, Moreau D, Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999; 56:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/29\">",
"      Mufson L, Dorta KP, Wickramaratne P, et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004; 61:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/30\">",
"      Rossell&oacute; J, Bernal G. The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. J Consult Clin Psychol 1999; 67:734.",
"     </a>",
"    </li>",
"    <li>",
"     Mufson, L, Pollack Dorta, K. Interpersonal therapy for depressed adolescents. In: Evidence-based Psychotherapies for Children and Adolescents. Guilford, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4328/abstract/32\">",
"      Hammen C, Rudolph K, Weisz J, et al. The context of depression in clinic-referred youth: neglected areas in treatment. J Am Acad Child Adolesc Psychiatry 1999; 38:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1228 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4328=[""].join("\n");
var outline_f4_14_4328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Choosing a therapist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COGNITIVE-BEHAVIORAL THERAPY (CBT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Description",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Studies of CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Continuation or maintenance phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Typical course of CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INTERPERSONAL PSYCHOTHERAPY FOR ADOLESCENTS (IPT-A)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Description",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Studies of IPT-A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Typical course of IPT-A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADJUNCT PSYCHOSOCIAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1228|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?24/42/25260\" title=\"form 1\">",
"      CBT techniques adolescents1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?5/1/5150\" title=\"form 2\">",
"      CBT techniques adolescents2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1228|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/48/23309\" title=\"table 1\">",
"      Depression rating scales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=related_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4329="Iron requirements and iron deficiency in adolescents";
var content_f4_14_4329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iron requirements and iron deficiency in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4329/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/14/4329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescence is a time of increased iron needs because of the expansion of blood volume and increases in muscle mass. The incidence of iron deficiency among adolescents appears to be rising [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/1\">",
"     1",
"    </a>",
"    ]; at particular risk are adolescent athletes and adolescents who limit their intake of meat products.",
"   </p>",
"   <p>",
"    Iron deficiency in adolescents is a complex disorder. The diagnosis often is controversial, and the effects on both physical endurance and cognitive performance in adolescents remain to be fully understood. These issues will be addressed here. Iron deficiency in infants and young children and in adults is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Third National Health and Nutrition Examination Survey (NHANES III) found a 9 percent incidence of iron deficiency and a 2 percent incidence of anemia among American females between the ages 12 and 15 years; the respective values were 11 and 3 percent in girls between the ages of 16 and 19 years. Less than 1 percent of adolescent males had iron deficiency&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/2\">",
"     2",
"    </a>",
"    ]. Studies in other countries have found higher rates of iron deficiency in male and female adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Some of the variation in incidence noted among different studies is related to the controversy regarding the appropriate laboratory cutoffs to make the diagnosis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with chronic illness, heavy menstrual blood loss (&gt;80",
"    <span class=\"nowrap\">",
"     mL/month),",
"    </span>",
"    or who are underweight or malnourished are at increased risk for iron deficiency and should be screened during health supervision or specialty clinic visits [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overweight and obese children also appear to be at increased risk for iron deficiency and should undergo screening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one study, data from NHANES III were examined for an association between iron deficiency and weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence of iron deficiency increased as body mass index increased from normal weight to &gt;85th percentile for age and sex to &gt;95th percentile for age and sex (2.1 percent, 5.3 percent, and 5.5 percent, respectively). Obesity was a risk factor for iron deficiency anemia in both boys and girls, but rates were approximately three times higher in girls. The etiology of anemia in obese individuals is uncertain but may be related to low-quality diets or increased needs relative to body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, adolescent athletes, particularly those participating in endurance training, following alternative diets (vegetarian), or females at menarche, appear to be at risk for iron deficiency and should be screened as part of the pre-sport physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=see_link\">",
"     \"The preparticipation sports examination in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IRON REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Recommended Dietary Allowance (RDA) for iron is 8 mg in boys and girls age 9 to 13 years, and 11 mg for boys and 15 mg for girls age 14 to 18 years. The value is increased to 27",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    for pregnant adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/11\">",
"     11",
"    </a>",
"    ]. This requirement is appreciably higher than the absorbed iron requirement because of the low rate of absorption of dietary iron.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Boys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron requirements increase from approximately 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of absorbed iron to approximately 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during pubertal growth in boys (",
"    <a class=\"graphic graphic_figure graphicRef80906 \" href=\"UTD.htm?2/57/2975\">",
"     figure 1",
"    </a>",
"    ). This increase is because of both the expanding blood volume of adolescence and an increase in hemoglobin concentration. By the end of adolescence, the iron requirement decreases to the previous level of 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/12\">",
"     12",
"    </a>",
"    ]. Data from a study in which isotopic methods were used suggest an average absorbed iron requirement of 1.46",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Girls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak requirement for absorbed iron in girls reaches a maximum of approximately 1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    during puberty and remains at about 1.3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    after puberty to replace menstrual blood loss (",
"    <a class=\"graphic graphic_figure graphicRef80906 \" href=\"UTD.htm?2/57/2975\">",
"     figure 1",
"    </a>",
"    ). There is a wide variation in this loss; an estimated about 20 percent of women require 2.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of iron or more. One hypothesis is that the cumulative effects of high iron needs and the tendency of girls to eat less high-iron containing foods (such as meat) leads to an increasing prevalence of iron deficiency during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/12\">",
"     12",
"    </a>",
"    ]. Data from a study in which isotopic methods were used suggest an average absorbed iron requirement of 1.15",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    during adolescence. However, uncertainties about menstrual loss make this value less certain and likely more variable than the value for boys [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STAGES OF IRON DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory manifestations of iron deficiency occur in several stages (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. These stages are defined by the extent of depletion, first of iron stores and then of iron available for hemoglobin synthesis. Eventually, the iron and hemoglobin deficiency is so severe that iron deficient red cell production occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first stage, iron stores can be depleted totally without causing anemia. The storage pool can be looked upon as a reserve of iron that can be utilized when the need for hemoglobin synthesis is increased (eg, with acute blood loss or growth in adolescents). Once these stores are depleted, the amount of iron present in the body is still within the \"labile\" iron pool from the daily turnover of red cells for normal hemoglobin synthesis, but the patient is now vulnerable to development of anemia should further iron losses occur (",
"      <a class=\"graphic graphic_figure graphicRef71736 \" href=\"UTD.htm?36/1/36895\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Further loss of iron results in anemia, which is initially normocytic with a normal absolute reticulocyte count (",
"      <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      More profound deficiency results in the classical hypochromia and microcytosis of iron-deficient erythropoiesis (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The erythropoietin (EPO) concentration is appropriately elevated in iron deficiency anemia, but the absolute reticulocyte count usually is not increased because iron deficiency (specifically a reduction in transferrin-bound plasma iron) becomes rate-limiting for erythropoiesis, thereby impairing the erythropoietic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual presenting symptoms of iron deficiency are caused primarily by anemia and include weakness, headache, irritability, and varying degrees of fatigue and exercise intolerance. However, many adolescents are asymptomatic and present with only anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency can impair cognitive function in adolescents. This impairment was illustrated in a study in which 81 adolescent girls with nonanemic iron deficiency (serum ferritin &le;12",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    with normal hemoglobin concentration) were randomly assigned to receive oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    (650 mg twice daily) or placebo for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/18\">",
"     18",
"    </a>",
"    ]. The girls who received iron showed an elevation in serum ferritin (27.3 versus 12.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the placebo group) and performed significantly better on a test of verbal learning and memory.",
"   </p>",
"   <p>",
"    Similar benefits of iron sufficiency were shown in a blinded placebo-controlled intervention trial in young women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/19\">",
"     19",
"    </a>",
"    ]. Women aged 18 to 35 years old with iron deficiency performed less well on a series of cognitive tasks than women with sufficient iron stores. After supplementation, an increase in serum ferritin was associated with a five- to sevenfold improvement in cognitive performance.",
"   </p>",
"   <p>",
"    In another trial of adolescent girls, improvements in lassitude, the ability to concentrate in school, and mood were reported by the girls who ingested iron compared with the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/20\">",
"     20",
"    </a>",
"    ]. The majority of girls who improved were hypoferremic at baseline and became normoferremic by the end of the study.",
"   </p>",
"   <p>",
"    Cross-sectional data regarding iron status from NHANES III (1988-1994) were compared with standardized test scores for 5398 children aged six to 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/21\">",
"     21",
"    </a>",
"    ]. Three percent of the children in this sample were iron deficient (abnormal values for any two of the following: free transferrin saturation, erythrocyte protoporphyrin, and serum ferritin). Compared to children with normal iron status, children with iron deficiency, with and without anemia, had lower average math scores (93.7 versus 86.4 and 87.4 percent for iron deficient children with and without anemia, respectively). Reading, verbal, and performance scores did not differ between the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia impairs exercise capacity in adolescents; a similar effect as well as easy fatigability may be seen with iron deficiency in the absence of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one study, for example, 14 iron-deficient nonanemic adolescent runners were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    (975",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/22\">",
"     22",
"    </a>",
"    ]. The mean ferritin concentration rose from 8.7 to 26.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in patients taking iron and fell from 10.6 to 8.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the placebo group. Treadmill endurance times improved significantly in the iron-treated runners (increase of 0.03 to 1.92 minutes) while declining in all seven controls (decrease of 0.07 to 1.30 minutes). No significant differences in gas exchange or cardiac measures occurred between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pica and pagophagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pica refers to a perverted appetite for substances not fit as food, such as clay or paper products. Pagophagia, or pica for ice, is considered quite specific for the iron deficiency state [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It may be present in children who are not anemic and responds rapidly to treatment with iron, often before any increase is noted in the hemoglobin concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Beeturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional manifestation of iron deficiency is beeturia, in which the ingestion of beets leads to the excretion of red urine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/26\">",
"     26",
"    </a>",
"    ]. This finding is caused by increased intestinal absorption and subsequent excretion of the reddish pigment betalaine (betanin). Betalaine, a redox indicator, is decolorized by ferric ions, which presumably explains the predisposition to beeturia in iron deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22449339\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proponents of screening for iron deficiency in adolescents cite the relatively high prevalence (particularly in females and athletes) and potential adverse consequences, including possible cognitive effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, the available screening tests are minimally invasive (blood drawing), and therapy is generally safe.",
"   </p>",
"   <p>",
"    However, opponents generally cite the relatively subtle health consequences and paucity of data regarding beneficial effects of iron supplementation. In the Norwegian study cited above, for example, the investigators calculated that to increase the hemoglobin concentration in one 14- to 15-year-old child, 59 adolescents would have to be screened and 16 given iron therapy; these observations led to the authors to conclude that screening adolescents for iron deficiency would have a minimal functional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22449346\">",
"    <span class=\"h2\">",
"     Whom to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for screening for anemia in adolescents vary. The",
"    <a class=\"external\" href=\"file://practice.aap.org/popup.aspx?aID=1625&amp;language=\">",
"     American Academy of Pediatrics",
"    </a>",
"    recommends that menstruating girls be screened annually by measuring hemoglobin concentration or hematocrit, and that boys be screened once during the peak growth period [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/27\">",
"     27",
"    </a>",
"    ]. The Centers for Disease Control (CDC) suggests screening all nonpregnant women every five to ten years, starting in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the discrepant recommendations, we suggest that screening decisions be considered by individual practitioners based on the risk factors of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/28\">",
"     28",
"    </a>",
"    ]. Risk factors include significant physical activity, especially in female adolescent athletes, vegetarian diets,",
"    <span class=\"nowrap\">",
"     malnutrition/underweight,",
"    </span>",
"    chronic illness, or history of heavy menstrual blood loss (&gt;80",
"    <span class=\"nowrap\">",
"     mL/month)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22449531\">",
"    <span class=\"h2\">",
"     How to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening recommendations for iron deficiency from the American Academy of Pediatrics suggest measurement of hemoglobin or hematocrit, at a minimum; patients with hemoglobin level of &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    are anemic and require further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/29\">",
"     29",
"    </a>",
"    ]. However, anemia is neither a sensitive nor a specific screen for iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/30\">",
"     30",
"    </a>",
"    ]. Therefore, a secondary evaluation for iron deficiency is suggested. In most clinical settings, the simplest and most cost-effective measurement is a Complete Blood Count (CBC), which will include measurements of hemoglobin, hematocrit, mean corpuscular volume, and red blood cell distribution width (RDW; a measure of variability in red cell size). For adolescents with risk factors for iron deficiency, measuring serum ferritin at the time of the initial screen facilitates the diagnosis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary laboratory values obtained when evaluating an adolescent for iron deficiency include a complete blood count with red blood cell indices and serum ferritin. In most cases, iron deficiency is identified by a low serum ferritin concentration and iron deficiency anemia by a hemoglobin concentration below 11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    combined with a low serum ferritin. The anemia typically is microcytic and hypochromic, with variable cell size (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ) (MCV &lt;70, RDW &gt;17). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link\">",
"     \"Mean corpuscular volume\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H5#H5\">",
"     \"Mean corpuscular volume\", section on 'Red blood cell distribution width'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    To identify iron deficiency, a serum ferritin concentration below 12",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is usually used. Both higher and lower cutoffs have been suggested in adolescents. However, use of lower cutoffs did not appear to improve sensitivity, and use of higher cutoffs had poor specificity, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a cutoff value for serum ferritin of 12",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      two studies in Sweden identified a 4 to 5 percent incidence of iron deficiency in adolescent boys and a 14 to 15 percent incidence in adolescent girls [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. None of these subjects was anemic (hemoglobin less than 11.0",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      A study utilizing a ferritin cut-off value of 16",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      to define iron deficiency identified iron deficiency in 40 percent of adolescent girls and 15 percent of adolescent boys [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/3\">",
"       3",
"      </a>",
"      ]. These are very high rates of iron deficiency, and use of a ferritin value this high to define iron deficiency has been challenged because of the rarity of anemia in this population, as well as the risks related to iron overload from unneeded supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Toxicity'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Similarly, a report from a Norwegian population of adolescents identified iron deficiency 25 percent of girls and 30 percent of boys using a high serum ferritin cutoff of 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/4\">",
"       4",
"      </a>",
"      ]. Subsequently, iron therapy was administered for three months; an increase in hemoglobin was induced in only 3 of 44 subjects, suggesting that most of the subjects did not actually have iron deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpretation of serum ferritin results is also complicated by the fact that ferritin is an acute phase reactant, with serum levels increasing in liver disease, inflammation, and malignancy. As an example, the synthesis and release of ferritin by hepatic cells is enhanced directly by inflammatory cytokines such as interleukin-1 and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, an adolescent with iron deficiency and an acute infection or a chronic inflammatory disease may have a \"falsely\" normal ferritin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other conditions can produce a mild hypochromic, microcytic anemia and be confused with iron deficiency anemia. These include mild hereditary anemias (alpha or beta thalassemia traits, hemoglobin E trait) and the anemia of chronic disease. A method to distinguish among these disorders is noted in the table (",
"    <a class=\"graphic graphic_table graphicRef65701 \" href=\"UTD.htm?43/41/44699\">",
"     table 2",
"    </a>",
"    ). Combined nutritional anemias (eg, vitamin B12 or folate deficiency with malabsorption states) also may lead to diagnostic confusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of iron deficiency may include both dietary measures and administration of iron supplements. For patients with mild or moderate degrees of iron deficiency (eg, no anemia or Hgb &gt;9",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    we suggest a trial of treatment with oral iron supplements (3 to 6 mg of elemental",
"    <span class=\"nowrap\">",
"     iron/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/27\">",
"     27",
"    </a>",
"    ]. Children weighing over 40 kg can be treated with standard adult dosing (150 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of elemental iron). Followup monitoring should be performed to ensure response to the supplementation, which also helps to confirm the diagnosis of iron deficiency. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Follow-up'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dietary iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary sources of iron are found in meat, grains, fruits, and vegetables (",
"    <a class=\"graphic graphic_table graphicRef83735 \" href=\"UTD.htm?25/13/25822\">",
"     table 3",
"    </a>",
"    ). Ready-to-eat cereal is a major contributor to iron intake among all children, more than three times higher than the contribution of beef and double that of yeast bread [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heme dietary sources (fish, poultry, and meat) have a higher bioavailability than do non-heme (vegetable) sources (30 versus 10 percent). In addition, intraluminal factors can affect absorption (",
"    <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"     table 4",
"    </a>",
"    ). Ascorbic acid enhances the absorption of non-animal sources of iron such as cereal, breads, fruits, and vegetables, whereas tannates (teas), bran foods rich in phosphates, and phytates inhibit iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. Thus, iron deficiency may be a particular problem in vegetarian children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=see_link&amp;anchor=H14#H14\">",
"     \"Vegetarian diets for children\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A relatively high calcium concentration also inhibits iron absorption. However, adaptation of iron absorption to high calcium intakes has been demonstrated, suggesting that this should not pose a significant clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Iron supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable controversy exists regarding the approaches to both the prevention and treatment of iron deficiency. Daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    , administered as elemental iron, 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, for an average period of six to eight weeks has been the standard of care. However, concerns remain about the poor tolerance of this approach for many people and the difficulty of accomplishing this regimen, especially in developing nations. Simpler approaches, such as the use of iron pots for cooking, might be effective in less-developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One alternative that has received attention is the use of weekly rather than daily supplements. In one study of Indonesian adolescents, supplementation with 60 mg of elemental iron (and retinol and vitamin C to increase iron absorption) once weekly was equally efficacious as daily supplementation with the same dose, but better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar results were demonstrated in a population of adolescent Nepalese girls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/46\">",
"     46",
"    </a>",
"    ]. A weekly approach is successful perhaps because it follows the natural pattern of mucosal cell iron turnover.",
"   </p>",
"   <p>",
"    However, the weekly approach has been sharply criticized by some in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/47\">",
"     47",
"    </a>",
"    ]. It may be more suitable for prevention of iron deficiency than for treatment, especially of established anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional considerations of absorption and side effects govern the choice of a supplementation regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Absorption",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iron is absorbed best from the duodenum and proximal jejunum. Thus, enteric coated or sustained release capsules, which release iron further down in the gastrointestinal tract, are counterproductive and expensive.",
"     </li>",
"     <li>",
"      Iron is absorbed as heme iron (from hemoglobin and myoglobin in meat) and nonheme iron (iron salts extracted from plant and dairy foods) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/50\">",
"       50",
"      </a>",
"      ]. Heme iron is highly bioavailable but comprises a small portion of dietary iron in most diets. Because of lack of heme iron, individuals consuming vegetarian diets may have increased iron requirements.",
"     </li>",
"     <li>",
"      The bioavailability of nonheme iron is affected by several intraluminal factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calcium, phytates, and tannates in food impair iron absorption to a variable degree. Phytates are present in legumes, rice, and grains. Thus, optimally, iron supplements are given separately from a meal. Concomitant administration of ascorbic acid can improve iron absorption with or without meals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron should be given two hours before, or four hours after, ingestion of antacids.",
"     </li>",
"     <li>",
"      Calcium inhibits the absorption of iron by as much as 60 percent. Thus, for individuals with iron deficiency, it is best to optimize absorption by trying to give iron supplements separately from calcium supplements. For individuals without iron deficiency, the supplements may be given in one pill for convenience, as it is likely that there is some adaptation to absorption when supplements are taken regularly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The iron preparation used should be based upon cost and effectiveness with minimal side effects. The least expensive preparation is iron sulfate tablets, which are usually provided in tablets containing 325 mg of iron salts, of which 65 mg is elemental iron [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron therapy can cause unpleasant gastrointestinal symptoms such as nausea and constipation. This seems to be related directly to the amount of elemental iron ingested. Thus, the reported low incidence of side effects for some preparations can be explained by their low elemental iron content.",
"   </p>",
"   <p>",
"    Gastrointestinal intolerance often can be reduced by altering the supplementation regimen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Taking iron supplements with food may reduce or eliminate gastrointestinal side effects. Food also may impair absorption of nonheme iron, but this effect may be minimized by concurrent administration of ascorbic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with persistent gastric intolerance may tolerate elixir of Feosol, which provides about 45 mg of elemental iron per 5 mL. Patients can titrate the dose down to the level at which the gastrointestinal symptoms become acceptable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms such as nausea and constipation are the most common side effects of iron supplementation. These are dose-related, and often can be solved by altering the supplementation regimen as described above.",
"   </p>",
"   <p>",
"    Acute iron intoxication (potentially fatal) usually occurs in small children; adolescents more commonly experience chronic iron overload, particularly in the setting of an underlying iron storage disorder. A rare form of juvenile hemochromatosis that is genetically and clinically distinct from the more usual adult form may present in adolescence with symptoms related to severe iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=see_link\">",
"     \"Acute iron poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H14#H14\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Juvenile hemochromatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Widespread screening for the more usual form of adult hemochromatosis is controversial. The possibility of universal screening may lead to a time in which many adolescents are identified as either homozygotes or heterozygotes for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4329/abstract/55\">",
"     55",
"    </a>",
"    ]; the implications of this approach for iron fortification policies aimed at children have not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemoglobin and hematocrit and red blood cell indices should be checked six to eight weeks after initiation of iron therapy to assess clinical improvement and therapeutic efficacy. This testing should be done when the child is healthy (without signs of a recent illness because a viral illness may cause a transient decrease in hemoglobin). If the hemoglobin (Hgb) has increased by 1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    therapy is continued and a CBC is retested every two to three months until the Hgb reaches the age-adjusted normal range. Iron supplements should then be continued for two to three more months to replace storage iron pools.",
"   </p>",
"   <p>",
"    If the microcytic anemia fails to improve after four weeks, the clinician should interview the patient to determine whether the supplement has been given at the appropriate dose and timing, and if there has been a significant intercurrent illness (which might cause a transient decrease in Hgb).",
"   </p>",
"   <p>",
"    Additional laboratory tests should be obtained to further evaluate the cause of anemia, including a serum ferritin, hemoglobin electrophoresis, vitamin B12 and folate levels, and testing several stools for occult blood. These results will help to rule out conditions that might simulate or complicate the IDA (",
"    <a class=\"graphic graphic_table graphicRef65701 \" href=\"UTD.htm?43/41/44699\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three different preparations available for parenteral iron therapy:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    , sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (saccharate). Iron",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    is the most commonly used preparation for pediatric patients. Sodium ferric gluconate and iron sucrose were developed for use in dialysis patients and are not approved by the US Food and Drug Administration for use in children.",
"   </p>",
"   <p>",
"    Parenteral iron therapy should be reserved for patients with severe, persistent anemia who have proven intolerance to oral supplements, malabsorption, or poor compliance to oral therapy. Parenteral iron should be used with caution because there is a 2 to 3 percent risk for anaphylaxis, some cases of which result in death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Parenteral iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion therapy is rarely necessary for severe IDA in children, unless hemoglobin concentrations are less than 4 to 5",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"    Adolescents may have more difficulty tolerating anemia and may benefit from transfusion at hemoglobin concentrations of less than 7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Transfusions should be reserved for patients in distress (heart rate greater than",
"    <span class=\"nowrap\">",
"     160/min,",
"    </span>",
"    respiratory rate greater than",
"    <span class=\"nowrap\">",
"     30/min,",
"    </span>",
"    lethargy, not feeding well) and should be used with caution (transfusion volumes of 5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over three to four hours) to avoid inducing heart failure. In adults, transfusion is not recommended in hemodynamically stable patients without end-organ ischemia unless the hemoglobin level is less than 7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22448854\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among adolescent girls in the United States, approximately 9 to 11 percent are iron deficient and 2 to 5 percent are anemic. Among adolescent boys, less than 1 percent are iron deficient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for iron deficiency include chronic illness, heavy menstrual blood loss (&gt;80",
"      <span class=\"nowrap\">",
"       mL/month),",
"      </span>",
"      underweight or undernutrition, endurance training, or vegetarian diets. In addition, girls and boys who are obese are more likely to be iron deficient than their normal-weight peers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Recommended Dietary Allowance (RDA) for iron is 8 mg in boys and girls age 9 to 13 years, and 11 mg for boys and 15 mg for girls age 14 to 18 years. The value is increased to 27",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      for pregnant adolescents. This requirement is appreciably higher than the absorbed iron requirement because of the low rate of absorption of dietary iron. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Iron requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory manifestations of iron deficiency occur in several stages (",
"      <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"       table 1",
"      </a>",
"      ), characterized by progressive degrees of anemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Stages of iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The usual presenting symptoms of iron deficiency are caused primarily by anemia and include weakness, headache, irritability, and varying degrees of fatigue and exercise intolerance. In addition iron deficiency can impair cognitive function, concentration, and exercise capacity. Occasionally iron deficiency may cause pica (particularly of ice), or beeturia (in which the ingestion of beets leads to the excretion of red urine). However, many adolescents are asymptomatic and present with only anemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for screening for anemia in adolescents vary. The American Academy of Pediatrics recommends that menstruating girls be screened annually by measuring hemoglobin concentration or hematocrit, and that boys be screened once during the peak growth period. We suggest that screening decisions also be modified by consideration of risk factors for iron deficiency, including high levels of physical activity, vegetarian diets, malnutrition or underweight, chronic illness, obesity, or history of heavy menstrual blood loss (&gt;80",
"      <span class=\"nowrap\">",
"       mL/month).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H22449346\">",
"       'Whom to screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most clinical settings, the simplest and most cost-effective screen for iron deficiency is to perform a Complete Blood Count (CBC), which will include measurements of hemoglobin, hematocrit, mean corpuscular volume, and red blood cell distribution width (RDW; a measure of variability in red cell size). For individuals with any of the above risk factors for iron deficiency, we suggest including serum ferritin. (See",
"      <a class=\"local\" href=\"#H22449531\">",
"       'How to screen'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Laboratory evaluation for iron deficiency includes a complete blood count with red blood cell indices and serum ferritin. In most cases, iron deficiency is identified by a low serum ferritin concentration and iron deficiency anemia by a hemoglobin concentration below 11.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      combined with a low serum ferritin (usually defined as less than 12",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      Because ferritin is an acute phase reactant, it will be increased by infection, inflammation, liver disease, and malignancy; ferritin values do not reflect iron stores in these clinical settings. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild or moderate degrees of iron deficiency (eg, no anemia or Hgb &gt;9",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"       table 1",
"      </a>",
"      ), we suggest a trial of treatment with oral iron supplements (3 to 6 mg of elemental",
"      <span class=\"nowrap\">",
"       iron/kg/day,",
"      </span>",
"      up to a maximum of 150 to 200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Follow up monitoring should be performed to ensure response to the supplementation, which also helps to confirm the diagnosis of iron deficiency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Follow-up'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/1\">",
"      Maeda M, Yamamoto M, Yamauchi K. Prevalence of anemia in Japanese adolescents: 30 years' experience in screening for anemia. Int J Hematol 1999; 69:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/2\">",
"      Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/3\">",
"      Hallberg L, Hult&eacute;n L, Lindstedt G, et al. Prevalence of iron deficiency in Swedish adolescents. Pediatr Res 1993; 34:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/4\">",
"      Eskeland B, Hunskaar S. Anaemia and iron deficiency screening in adolescence: a pilot study of iron stores and haemoglobin response to iron treatment in a population of 14-15-year-olds in Norway. Acta Paediatr 1999; 88:815.",
"     </a>",
"    </li>",
"    <li>",
"     Green, M. Bright Futures: National guidelines for health supervision of infants, children, and adolescents. National Center for Education in Maternal and Child Health, Arlington, VA 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/6\">",
"      Pinhas-Hamiel O, Newfield RS, Koren I, et al. Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord 2003; 27:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/7\">",
"      Nead KG, Halterman JS, Kaczorowski JM, et al. Overweight children and adolescents: a risk group for iron deficiency. Pediatrics 2004; 114:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/8\">",
"      Beard JL. Iron requirements in adolescent females. J Nutr 2000; 130:440S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/9\">",
"      Hord JD. Anemia and coagulation disorders in adolescents. Adolesc Med 1999; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/10\">",
"      Merkel D, Huerta M, Grotto I, et al. Prevalence of iron deficiency and anemia among strenuously trained adolescents. J Adolesc Health 2005; 37:220.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Iron in: Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and Zinc. National Academy Press, Washington DC, 2000; p. 339.",
"    </li>",
"    <li>",
"     Dallman, PR. Changing iron needs from birth through adolescence. In: Nutritional Anemias, Fomon, SJ, Zlotkin, S (Ed), Nestle Nutrition Workship Series, vol 30, Nestec, Ltd. Vevey/Raven Press, Ltd, New York 1992. p. 29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/13\">",
"      Fomon SJ, Drulis JM, Nelson SE, et al. Inevitable iron loss by human adolescents, with calculations of the requirement for absorbed iron. J Nutr 2003; 133:167.",
"     </a>",
"    </li>",
"    <li>",
"     Brittenham, GM. Disorders of iron metabolism: Iron deficiency and overload. In: Hematology Basic Principles and Practice, 2nd ed, Hoffman, R, Benz, EJ Jr, Shattil, SJ, et al (Eds), Churchill Livingstone, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/15\">",
"      Cook JD, Skikne BS. Iron deficiency: definition and diagnosis. J Intern Med 1989; 226:349.",
"     </a>",
"    </li>",
"    <li>",
"     Bridges, KR, Seligman, PA. Disorders of iron metabolism. In: Blood: Principles &amp; Practice of Hematology, Handin, RI, Lux, SE, Stossel, TP (Eds), 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/17\">",
"      Crosby, WH. Physiology and pathophysiology of iron metabolism. Hosp Pract 1990; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/18\">",
"      Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996; 348:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/19\">",
"      Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007; 85:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/20\">",
"      Ballin A, Berar M, Rubinstein U, et al. Iron state in female adolescents. Am J Dis Child 1992; 146:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/21\">",
"      Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics 2001; 107:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/22\">",
"      Rowland TW, Deisroth MB, Green GM, Kelleher JF. The effect of iron therapy on the exercise capacity of nonanemic iron-deficient adolescent runners. Am J Dis Child 1988; 142:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/23\">",
"      Rowland TW, Kelleher JF. Iron deficiency in athletes. Insights from high school swimmers. Am J Dis Child 1989; 143:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/24\">",
"      Brown WD, Dyment PG. Pagophagia and iron deficiency anemia in adolescent girls. Pediatrics 1972; 49:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/25\">",
"      Rector WG Jr. Pica: its frequency and significance in patients with iron-deficiency anemia due to chronic gastrointestinal blood loss. J Gen Intern Med 1989; 4:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/26\">",
"      Tunnessen WW, Smith C, Oski FA. Beeturia. A sign of iron deficiency. Am J Dis Child 1969; 117:424.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of Pediatrics. Screening for iron deficiency, in: Pediatric Nutrition Handbook, 6th ed, Kleinman, RE (Ed). American Academy of Pediatrics, Elk Grove Village, IL 2009. p. 419.",
"    </li>",
"    <li>",
"     Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 1998; 47(RR-3):1. Available at: www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6.section.4828 (Accessed on May 31, 2007).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Recommendations for preventive pediatric health care (periodicity schedule). Available at: practice.aap.org/content.aspx?aid=1599 (Accessed on August 4, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/30\">",
"      White KC. Anemia is a poor predictor of iron deficiency among toddlers in the United States: for heme the bell tolls. Pediatrics 2005; 115:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/31\">",
"      Bergstr&ouml;m E, Hernell O, L&ouml;nnerdal B, Persson LA. Sex differences in iron stores of adolescents: what is normal? J Pediatr Gastroenterol Nutr 1995; 20:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/32\">",
"      Samuelson G, Bratteby LE, Berggren K, et al. Dietary iron intake and iron status in adolescents. Acta Paediatr 1996; 85:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/33\">",
"      Olsson KS, Marsell R, Ritter B, et al. Iron deficiency and iron overload in Swedish male adolescents. J Intern Med 1995; 237:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/34\">",
"      Tran TN, Eubanks SK, Schaffer KJ, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997; 90:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/35\">",
"      Subar AF, Krebs-Smith SM, Cook A, Kahle LL. Dietary sources of nutrients among US children, 1989-1991. Pediatrics 1998; 102:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/36\">",
"      Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/37\">",
"      Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut 1975; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/38\">",
"      Hallberg L, Rossander L, Sk&aring;nberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr 1987; 45:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/39\">",
"      Hallberg L, Hulth&eacute;n L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr 2000; 71:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/40\">",
"      Cook JD. Adaptation in iron metabolism. Am J Clin Nutr 1990; 51:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/41\">",
"      Ames SK, Gorham BM, Abrams SA. Effects of high compared with low calcium intake on calcium absorption and incorporation of iron by red blood cells in small children. Am J Clin Nutr 1999; 70:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/42\">",
"      M&oslash;lgaard C, Kaestel P, Michaelsen KF. Long-term calcium supplementation does not affect the iron status of 12-14-y-old girls. Am J Clin Nutr 2005; 82:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/43\">",
"      Bendich A. Calcium supplementation and iron status of females. Nutrition 2001; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/44\">",
"      Adish AA, Esrey SA, Gyorkos TW, et al. Effect of consumption of food cooked in iron pots on iron status and growth of young children: a randomised trial. Lancet 1999; 353:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/45\">",
"      Angeles-Agdeppa I, Schultink W, Sastroamidjojo S, et al. Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents. Am J Clin Nutr 1997; 66:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/46\">",
"      Shah BK, Gupta P. Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls. Arch Pediatr Adolesc Med 2002; 156:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/47\">",
"      Baynes RD, Cook JD. Current issues in iron deficiency. Curr Opin Hematol 1996; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/48\">",
"      Viteri FE. Iron supplementation for the control of iron deficiency in populations at risk. Nutr Rev 1997; 55:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/49\">",
"      Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med 1984; 144:471.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Iron in: Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and Zinc. National Academy Press, Washington DC, 2000; p. 292-294.",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Iron in: Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and Zinc. National Academy Press, Washington DC, 2000; p. 311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/52\">",
"      Siegenberg D, Baynes RD, Bothwell TH, et al. Ascorbic acid prevents the dose-dependent inhibitory effects of polyphenols and phytates on nonheme-iron absorption. Am J Clin Nutr 1991; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/53\">",
"      Boggs DR. Fate of a ferrous sulfate prescription. Am J Med 1987; 82:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/54\">",
"      Kelly AL, Rhodes DA, Roland JM, et al. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4329/abstract/55\">",
"      Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology 1995; 22:1720.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5350 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4329=[""].join("\n");
var outline_f4_14_4329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22448854\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IRON REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STAGES OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pica and pagophagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Beeturia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22449339\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22449346\">",
"      Whom to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22449531\">",
"      How to screen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dietary iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Iron supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Intolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22448854\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5350|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/57/2975\" title=\"figure 1\">",
"      Iron needs during adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/1/36895\" title=\"figure 2\">",
"      Overview of iron homeostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5350|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/58/33708\" title=\"table 1\">",
"      Lab tests in iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/41/44699\" title=\"table 2\">",
"      Laboratory differential dx IDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/13/25822\" title=\"table 3\">",
"      Dietary sources of iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 4\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4330="Management of alopecia areata";
var content_f4_14_4330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of alopecia areata",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Andrew G Messenger, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/14/4330/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/14/4330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alopecia areata is a chronic, relapsing immune-mediated inflammatory disorder affecting hair follicles that causes nonscarring hair loss. The severity of the disorder ranges from small patches of alopecia on any hair-bearing area to the complete loss of scalp, eyebrow, eyelash, and body hair.",
"   </p>",
"   <p>",
"    Although up to 50 percent of patients who present with patchy alopecia areata experience spontaneous hair regrowth within one year, most will relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ]. The unpredictable course of the disease and the psychological distress associated with hair loss prompt many patients to seek therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\", section on 'Course of disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of alopecia areata involves both addressing the psychological needs of the patient and offering treatment to patients who desire intervention. A variety of topical, intralesional, and systemic agents, as well as devices, have been used for alopecia areata, but the response to treatment varies widely, and few well-designed clinical trials have evaluated these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for the management of alopecia areata will be discussed here. The clinical manifestations and diagnosis of the disorder are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the relative safety and the available, although limited, evidence for the efficacy of these agents, intralesional or topical corticosteroids are the initial treatment for most patients with patchy alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ]. Topical immunotherapy can be used as first-line treatment for patients with extensive disease (greater than 50 percent scalp hair loss).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest intralesional corticosteroids as the preferred therapy for adults with isolated patches of hair loss who desire treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of intralesional corticosteroids for alopecia areata. One study reported regrowth of tufts of hair at 33 of 34 sites injected with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide in 11 patients and at 16 of 25 sites injected with triamcinolone acetonide in 17 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/3\">",
"     3",
"    </a>",
"    ]. Another study reported complete regrowth of hair after four months in 40 of 62 patients (63 percent) treated with monthly injections of triamcinolone acetonide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injections should be performed on both existing and newly forming patches of alopecia. The goals of treatment are to promote regrowth and limit hair loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The affected area may be pretreated with a topical anesthetic cream (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      2.5 percent and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      2.5 percent EMLA cream). The cream is applied generously, and is placed under occlusion with a tightly fitting shower cap or plastic wrap 1.5 to 2 hours before treatment. The cream is removed immediately before injection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      2.5 to 5.0",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      is injected into the upper subcutis on the face for eyebrow or beard involvement; concentrations of 5 to 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      are injected into the upper subcutis on the scalp. Small volumes (0.1 mL or less) are injected into multiple sites 1 cm apart (",
"      <a class=\"graphic graphic_picture graphicRef80429 \" href=\"UTD.htm?24/11/24757\">",
"       picture 1",
"      </a>",
"      ). The dose per visit is largely determined by the extent of disease and patient tolerance but is usually around 20 mg or less on the scalp. Up to 40 mg of triamcinolone may be injected per session.",
"     </li>",
"     <li>",
"      New growth is usually visible within four weeks. The treatment may be repeated as necessary every four to six weeks, and is stopped once regrowth is complete. If there is no response after six months, treatment should be discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/5\">",
"       5",
"      </a>",
"      ] and alternative treatments may be attempted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local skin atrophy is a consistent side effect but usually resolves within a few months. Other cutaneous side effects include telangiectasias and hypopigmentation. Facial injection should be approached cautiously, particularly in patients with pigmented skin, in whom hypopigmentation can be prominent. Non-dermatologists should consider referring patients who need facial injections to a dermatologist. The risk for adrenal suppression in patients treated with intralesional corticosteroid injections into the skin has not been formally studied [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     For extensive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive disease are less frequently treated with intralesional corticosteroids due to concern for lower efficacy in this subgroup and the large number of injections required. One retrospective study reported superior efficacy of topical immunotherapy over intralesional corticosteroids for patients with patches of hair loss exceeding 50 cm",
"    <sup>",
"     2",
"    </sup>",
"    in size [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Still, some patients with extensive disease respond to treatment. In one case series, 6 out of 10 patients with greater than 50 percent scalp hair loss responded well to intralesional corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/10\">",
"     10",
"    </a>",
"    ]. Pain of injection was managed with topical anesthetics. None of the patients in this study exhibited clinical signs of adrenal insufficiency; however, laboratory assessment for adrenal suppression was not performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potent topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;While potent topical corticosteroids are frequently used to treat alopecia areata, evidence for their effectiveness is limited. We usually reserve first-line therapy with topical corticosteroids for children and adults who cannot tolerate intralesional injections. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Considerations for the treatment of children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of studies investigating the efficacy of topical corticosteroids for alopecia areata include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial in 70 patients with patchy alopecia areata randomly assigned patients to apply either 0.25%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24740?source=see_link\">",
"       desoximetasone",
"      </a>",
"      cream or placebo twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/11\">",
"       11",
"      </a>",
"      ]. After 12 weeks of therapy, a non-statistically significant greater number of patients treated with desoximetasone experienced complete regrowth of hair (58 versus 39 percent, relative risk 1.5, 95% CI 0.83-2.59). More patients treated with the corticosteroid experienced at least mild improvement and this result did achieve statistical significance.",
"     </li>",
"     <li>",
"      A 12-week randomized trial in which 105 patients with localized alopecia areata were randomized to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      valerate 0.1% foam applied twice daily, intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide (10",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      administered every three weeks, or topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.1% ointment applied twice daily found &gt;75 percent hair regrowth in 54, 60, and 0 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/12\">",
"       12",
"      </a>",
"      ]. Of note, 27 patients dropped out of the study prior to completion and were not included in the analysis of data.",
"     </li>",
"     <li>",
"      A trial in 34 patients with moderate to severe alopecia areata randomly assigned treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% foam to one side of the scalp and vehicle to the other side [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/13\">",
"       13",
"      </a>",
"      ]. After 12 weeks of treatment, more sites treated with clobetasol had at least 50 percent regrowth of hair (7 of 34 versus 1 of 34).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       Clobetasol",
"      </a>",
"      propionate applied under an occlusive dressing may be effective in some patients. In a study of 28 patients who had alopecia totalis and alopecia universalis for a mean duration of seven years, clobetasol propionate 0.05 percent ointment applied under an occlusive plastic film on six out of seven nights for six months resulted in long-term hair regrowth in five patients (17.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/14\">",
"       14",
"      </a>",
"      ]. The study initially had patients use the treatment on only one side of the scalp, and no hair regrowth occurred on the untreated side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The low response rate seen in the latter two studies may reflect the greater severity of disease in the patients enrolled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically treat with a high potency topical corticosteroid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate 0.05 percent (cream, lotion, ointment) applied to affected areas and 1 cm beyond twice daily (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). The entire scalp is treated if a large area is involved. Therapy should be evaluated after three months of use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to intralesional corticosteroids, side effects of topical therapy include local skin atrophy, telangiectasias, hypopigmentation, and adrenal suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Application under occlusion increases the potency of topical corticosteroids. Given the potential for increasing side effects, we do not recommend this method of application in the absence of additional studies demonstrating safety and long-term efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Topical immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical immunotherapy is probably the most effective treatment for patients with extensive or recurrent scalp involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The procedure is usually performed by dermatologists.",
"   </p>",
"   <p>",
"    A potent contact allergen is applied weekly to the scalp to precipitate an allergic contact dermatitis. The resultant mild inflammatory reaction is associated with hair regrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The reason for this response remains unknown, but an immunomodulatory effect on the inflammatory infiltrate surrounding affected hair follicles is thought to play a role. Theories for the mechanism of action have focused on the inhibition of the pathologic immune response via antigenic competition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/17\">",
"     17",
"    </a>",
"    ], the induction of lymphocyte apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/18\">",
"     18",
"    </a>",
"    ], or an effect on the type or function of lymphocytes in the inflammatory infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled studies have found variable rates of response, but as many as 40 to 60 percent of patients may achieve cosmetically significant hair regrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/15,22-25\">",
"     15,22-25",
"    </a>",
"    ]. Patients with severe or long-standing disease may be less likely to respond to topical immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/15,26,27\">",
"     15,26,27",
"    </a>",
"    ]. Relapse rates are approximately 60 percent, with a mean time to relapse of 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical immunotherapy can be performed with diphenylcyclopropenone (DPCP), squaric acid dibutyl ester (SADBE), or dinitrochlorobenzene (DNCB). DNCB was the first topical sensitizer used for the treatment of alopecia areata, but is now infrequently used due to concerns that it may be mutagenic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/28\">",
"     28",
"    </a>",
"    ]. The agents for topical immunotherapy are typically purchased from a chemical distributor. The solutions are subsequently prepared by a pharmacy or the clinician.",
"   </p>",
"   <p>",
"    When both agents are available, DPCP is often favored over SADBE because it is less expensive and more stable in solution. SADBE must be refrigerated. DPCP is degraded by light, and should be stored in an amber glass bottle or another protective container.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical immunotherapy with DPCP begins with the application of a 2% solution to a small (eg, 4x4 cm) area on the scalp to sensitize the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"       1",
"      </a>",
"      ]. One to two weeks later, treatment is initiated with the application of a 0.001% concentration of the allergen to the affected areas.",
"     </li>",
"     <li>",
"      Patients should be instructed to wash off DPCP after 24 to 48 hours. While the product is on the skin, the treated areas should be protected from sun exposure with an opaque scarf or hat.",
"     </li>",
"     <li>",
"      For patients who exhibit a severe eczematous response to sensitization, an additional week should pass before starting treatment, and an even lower initial concentration of DPCP should be used.",
"     </li>",
"     <li>",
"      Treatments are repeated once weekly with slowly increasing concentrations of DPCP to a maximum concentration of 2%. The concentration that induces a mild dermatitis is utilized for all subsequent treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs of hair growth are expected by approximately three months, and the frequency of treatment is reduced once maximal hair growth is attained [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. Most clinicians discontinue therapy if there is no response after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/29\">",
"     29",
"    </a>",
"    ]; however, improvement requiring longer courses of DPCP therapy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The procedure for sensitization and treatment with SADBE is similar. Sensitization is performed with a 2% solution, and is followed by weekly 24 hour applications of the agent. Treatment begins with a low concentration solution (such as 0.0001%) that is increased until mild dermatitis is elicited. Opinions vary on whether patients should be allowed to apply treatments at home [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe dermatitis is a potential side effect of topical immunotherapy. If a vesicular or bullous reaction occurs, the contact allergen should be washed from the skin and treatment with a topical corticosteroid should be initiated. Other potential side effects include lymphadenopathy, urticaria, vitiligo, and dyschromia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/5\">",
"     5",
"    </a>",
"    ]. Use in pregnant women is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-line options for the treatment of alopecia areata may be used alone or in combination with first line interventions. Compared with intralesional corticosteroids and topical immunotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     anthralin",
"    </a>",
"    appear to be less efficacious. PUVA is considered a second-line therapy due to the potential for long term adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Minoxidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the counter topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    is used twice daily alone or in combination with intralesional or topical corticosteroids in children and adults.",
"   </p>",
"   <p>",
"    Randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    have been small, and some [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/32\">",
"     32",
"    </a>",
"    ] trials have found evidence of benefit, at least for patients with limited alopecia areata.",
"   </p>",
"   <p>",
"    While there may be a dose response effect with the 5% solution being more effective than the 2% solution [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/33\">",
"     33",
"    </a>",
"    ], few patients achieve cosmetically significant regrowth. If used,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    should be tried for three months before evaluating effectiveness.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     Minoxidil",
"    </a>",
"    is not effective in patients with total loss of scalp hair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/32\">",
"     32",
"    </a>",
"    ]. Treatment does not induce remission in patients with extensive or patchy alopecia areata; continued application is required to maintain growth. Topical minoxidil is generally well tolerated but can lead to unwanted growth of facial hair in approximately 3 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/34\">",
"     34",
"    </a>",
"    ]. Pruritus or dermatitis is an occasional adverse event [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/35\">",
"     35",
"    </a>",
"    ]; a foam formulation is less likely to induce these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/36\">",
"     36",
"    </a>",
"    ]. Unlike the solution formulation, propylene glycol (a common allergen) is not present in minoxidil foam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anthralin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     Anthralin",
"    </a>",
"    cream is sometimes used as a second-line approach, although evidence of its effectiveness is limited to case series without adequate controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ]. Anthralin is an irritant agent that is mainly used to treat patients with psoriasis.",
"   </p>",
"   <p>",
"    Short-contact therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     anthralin",
"    </a>",
"    is performed by applying anthralin 0.5 or 1% cream to the affected areas for 20 to 30 minutes daily, followed by rinsing the cream off with cool to lukewarm water, and washing the treated area with any shampoo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/5\">",
"     5",
"    </a>",
"    ]. The time of contact is increased by 10 minutes every two weeks up to one hour or to the time required to elicit a mild dermatitis. Therapy is then continued at that exposure time.",
"   </p>",
"   <p>",
"    Alternatively, treatment can be initiated with application of a 0.1% concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     anthralin",
"    </a>",
"    to the scalp for 10 to 20 minutes. Tolerance to irritation is built up by gradually increasing (over a period of days) the time that the anthralin is left on the affected area, eventually reaching tolerance for leaving anthralin on overnight. The concentration of anthralin can be increased up to 2% as tolerated.",
"   </p>",
"   <p>",
"    An irritant reaction with erythema and scaling is desired but should not be allowed to become frankly vesicular. Mild irritation is expected and preferred over severe irritation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     Anthralin",
"    </a>",
"    should be used for three months before reevaluating for treatment effectiveness.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     Anthralin",
"    </a>",
"    will stain hair, skin, and clothing brown. Patients should wash their hands with cool to lukewarm water immediately after application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Photochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photochemotherapy is a treatment option for alopecia areata. Psoralen plus UVA therapy (PUVA) can be administered with the psoralen delivered topically as a gel or paint, or orally.",
"   </p>",
"   <p>",
"    Several uncontrolled series have suggested efficacy rates of PUVA of 60 to 65 percent, though with a high relapse rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Other series have found efficacy rates no higher than might be expected without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial of photochemotherapy may be reasonable in patients with extensive alopecia areata (more than 75 percent of scalp involved), alopecia totalis, or alopecia universalis when topical immunotherapy is contraindicated or unacceptable to the patient. Treatment is usually for four to six months.",
"   </p>",
"   <p>",
"    Long-term treatment with PUVA has been associated with an increased risk for cutaneous malignancy. Clinicians should consider this risk during treatment with PUVA therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapies are occasionally used for severe alopecia areata. A high likelihood of relapse and the potential adverse effects of these drugs limit their use to refractory cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoid therapy may induce hair growth in alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;The efficacy of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper (from 40 mg to 0 mg over the course of six weeks in patients weighing at least 40 kg) was investigated in a prospective study of 32 children and adults with alopecia areata, including 16 patients with alopecia totalis or universalis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/43\">",
"     43",
"    </a>",
"    ]. After six weeks, 13 patients achieved at least 50 percent hair regrowth, including four patients with 75 to 99 percent hair loss at baseline and four patients with alopecia universalis. Two patients worsened during prednisone therapy.",
"   </p>",
"   <p>",
"    Although systemic glucocorticoids appear to stimulate hair growth, the adverse effects associated with these agents limit the duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/44\">",
"     44",
"    </a>",
"    ], and recurrence of hair loss frequently occurs after the discontinuation of treatment. A subsequent vehicle-controlled randomized trial phase of the study described above suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    therapy may be useful for prolonging the response to treatment after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/43\">",
"     43",
"    </a>",
"    ]. Among patients who demonstrated at least 25% improvement at the end of prednisone therapy, six of seven patients who began thrice daily applications of minoxidil 2% solution after prednisone versus one of seven patients in the vehicle group maintained the response to treatment or had evidence of continued improvement at the week 12 assessment. By week 20, three of seven patients in the minoxidil group and none of four patients in the vehicle group demonstrated these findings, and the difference between the two groups was no longer statistically significant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regimens that involve pulsed oral glucocorticoids may also induce hair regrowth in some patients. In the only controlled trial, 43 patients were treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    200 mg or placebo once weekly for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients receiving prednisolone showed better hair regrowth at six months, but this was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/46\">",
"     46",
"    </a>",
"    ]. No significant side effects have been reported in published series but cannot be ruled out, and long-term benefits have not been shown.",
"   </p>",
"   <p>",
"    In addition, in clinical practice, short courses of systemic glucocorticoids (eg, 40 to 60 mg per day in adults or 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in children tapered over four to six weeks) are occasionally utilized to halt rapid disease progression in patients with widespread active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    is a drug with immunosuppressive and immunomodulatory properties. Uncontrolled studies and a retrospective chart review have reported successful therapy in approximately one-quarter of patients with alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, relapse rates of up to 45 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may include gastrointestinal distress, headache, fever, rash, and less frequently hematologic disorders and hepatotoxicity. Starting therapy with a low dose may decrease gastrointestinal symptoms. Patients can be treated with 0.5 g twice daily for one month, followed by 1 g twice daily for one month and 1.5 g twice daily for at least three months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Complete blood cell counts and liver function tests should be closely monitored during the first three months of therapy, and every three to six months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case series in 22 patients with alopecia totalis or universalis suggested benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/50\">",
"     50",
"    </a>",
"    ]. In our experience, treatment with methotrexate has been disappointing, and methotrexate therapy has important toxicities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    induced temporary hair regrowth in a series of six patients with alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/51\">",
"     51",
"    </a>",
"    ]. We do not recommend the use of the drug due to the potential for serious adverse effects and the high rate of relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of alopecia areata during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because alopecia areata is considered to be an immune-mediated disorder, attempts to treat with biologic agents that directly or indirectly alter T cell function have been made. With the exception of isolated case reports, these drugs have not been shown to be effective for alopecia areata.",
"   </p>",
"   <p>",
"    Tumor necrosis factor (TNF)-alpha inhibitors have not shown efficacy in the treatment of alopecia areata. An open-label study with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    revealed no efficacy of etanercept for the treatment of moderate to severe alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, patients who have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , or etanercept for other autoimmune disorders have developed alopecia areata during the course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/57-64\">",
"     57-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alefacept is a fusion protein that binds to CD2 and inhibits T-cell activation that is no longer marketed in North America. In a small randomized trial, alefacept therapy was ineffective for the treatment of severe alopecia areata (50 to 90 percent patchy scalp hair loss) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/65\">",
"     65",
"    </a>",
"    ]. Partial responses of alopecia areata and alopecia universalis to treatment with alefacept were anecdotally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the discontinuation of production of efalizumab, a recombinant humanized monoclonal antibody against CD11a, case reports documented successful responses to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, a randomized trial found that efalizumab was not effective for alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/70\">",
"     70",
"    </a>",
"    ]. Efalizumab was removed from the market in 2009 due to reports of the development of progressive multifocal leukoencephalopathy in patients taking the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement following treatment with the excimer laser, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    , and fractional photothermolysis has been reported. However, further studies are necessary before any of these agents can be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Excimer laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excimer laser emits monochromatic UVB light at a wavelength of 308 nm. Its mechanism of action in alopecia areata is thought to involve the induction of T cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In a few small studies and case reports, treatment with the excimer laser was associated with improvement in patchy alopecia areata of the scalp [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/72,74-77\">",
"     72,74-77",
"    </a>",
"    ]. Patients with lesions on the extremities, alopecia totalis, or alopecia universalis have not responded to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/72,74,77\">",
"     72,74,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Topical bexarotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    randomized, single-blind trial, patients with alopecia areata applied topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/10/31904?source=see_link\">",
"     bexarotene",
"    </a>",
"    , a retinoid, to one side of the scalp [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/78\">",
"     78",
"    </a>",
"    ]. After 24 weeks, 5 out of 42 patients (12 percent) exhibited at least 50 percent hair regrowth on the treated side of the scalp. An additional 6 patients (14 percent) had regrowth on both sides of the scalp. The reason for the bilateral hair growth is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550499787\">",
"    <span class=\"h2\">",
"     Capsaicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of a pilot study of two patients and a small randomized trial, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    may be able to stimulate vellus hair growth in alopecia areata through effects on the perifollicular neuroimmunological system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, an ability of the drug to induce cosmetically significant hair growth has not been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fractional photothermolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete hair regrowth following multiple treatments with a fractional photothermolysis laser has been reported in a patient with alopecia areata refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and topical and intralesional corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643374672\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for involvement of neuropeptides in the pathogenesis of alopecia areata and a case report in which alopecia areata associated with neuralgiform head pain improved after botulinum toxin A injection suggested that botulinum toxin might be useful for alopecia areata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/82\">",
"     82",
"    </a>",
"    ]. However, additional data to support a beneficial effect are lacking. In an uncontrolled prospective study of seven patients with alopecia areata (two with patchy disease and five with alopecia totalis or universalis) only one patient with previously untreated patchy alopecia areata of short duration had hair regrowth; none of the other patients (all of whom had long-standing alopecia areata that failed to respond to at least one other therapy) improved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/83\">",
"     83",
"    </a>",
"    ]. Since spontaneous resolution of patchy alopecia areata is common, hair regrowth may not have been related to the treatment. Further studies are necessary to determine whether botulinum toxin may be effective for some patients with alopecia areata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     EYELASH ALOPECIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established treatments for the local treatment of eyelash disease. Topical prostaglandin analogues have been studied for this purpose, but the efficacy of these drugs remains uncertain. False eyelashes are a cosmetic option for patients. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Cosmetic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prostaglandin analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrichosis of the eyelashes may occur as a side effect of glaucoma therapy with the topical prostaglandin analogues",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/42/41635?source=see_link\">",
"     latanoprost",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44115?source=see_link\">",
"     bimatoprost",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. Knowledge of this effect led to clinical studies of the efficacy of these drugs for alopecia areata involving the eyelashes and eyebrows.",
"   </p>",
"   <p>",
"    The majority of studies, including a 16-week randomized trial of 11 patients, have shown no benefit of these drugs for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. However, a nonrandomized, prospective study reported benefit with a longer course of therapy. Of 44 patients with eyelash alopecia treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/42/41635?source=see_link\">",
"     latanoprost",
"    </a>",
"    ophthalmic solution for two years, complete or moderate regrowth occurred in 17.5 and 27.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/91\">",
"     91",
"    </a>",
"    ]. None of the 10 patients who did not receive the drug attained similar levels of response.",
"   </p>",
"   <p>",
"    Additional studies are necessary to determine whether prostaglandin analogues should be utilized for the treatment of periocular alopecia areata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     INEFFECTIVE THERAPIES",
"    </span>",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/92\">",
"     92",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/95,96\">",
"     95,96",
"    </a>",
"    ], and photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/97-99\">",
"     97-99",
"    </a>",
"    ] are not effective for alopecia areata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     CONSIDERATIONS FOR THE TREATMENT OF CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to concerns about treatment tolerability and potential side-effects, therapeutic options for children are more limited than for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/100\">",
"     100",
"    </a>",
"    ]. Although intralesional glucocorticoids are often used as initial treatment for adults with alopecia areata, this form of therapy may be difficult for young children to tolerate, even with the use of topical anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, topical therapies are the primary therapeutic modality in this age group, with potent topical glucocorticoids as the first-line treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/100,102\">",
"     100,102",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and topical immunotherapy are additional options for the treatment of children.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/18/20771?source=see_link\">",
"     Anthralin",
"    </a>",
"    may also be used, but the significant irritation reaction can limit its use in children.",
"   </p>",
"   <p>",
"    As with adults, the use of oral glucocorticoids for extensive and progressive alopecia areata may induce hair regrowth, but patients often relapse upon the cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/103\">",
"     103",
"    </a>",
"    ]. The use of long-term systemic glucocorticoids is generally not recommended due to concern for systemic side effects including growth retardation, loss of bone density, and adrenal suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of PUVA therapy in children with alopecia areata have had variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/102\">",
"     102",
"    </a>",
"    ]. PUVA is not favored for the use in children due to its association with cutaneous malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link&amp;anchor=H31513976#H31513976\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Skin cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The psychological effects of hair loss are often of concern in children, and particularly adolescents, with alopecia areata. Adolescents suffering from alopecia areata have increased rates of psychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Counseling and support services may be indicated. (See",
"    <a class=\"local\" href=\"#H550499604\">",
"     'Counseling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A referral to Locks of Love, a non-profit organization that provides hair prostheses for children younger than 18 years, may benefit patients with alopecia totalis or alopecia universalis (",
"    <a class=\"external\" href=\"file://www.locksoflove.org/\">",
"     www.locksoflove.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     COSMETIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female patients with extensive alopecia areata will usually require a wig or hairpiece. Wigs are generally less successful in men where hair styles, such as shaving the scalp, are often a more acceptable approach. Eyebrow tattooing can be helpful for loss of eyebrows. Patients with alopecia of the eyelashes may choose to apply false eyelashes. False eyelashes are widely available in pharmacies and beauty supply stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550499604\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educating patients about alopecia areata, discussing realistic expectations for treatment, and offering resources for psychological support are important components of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the majority of patients, alopecia areata is a cosmetic concern although it can occasionally cause physical disability (eg, where there is eyelash involvement, loss of nasal hairs, or marked nail dystrophy). Nevertheless, the cosmetic importance of hair is such that alopecia areata can cause severe emotional problems, particularly in children and young women, though by no means restricted to these groups.",
"   </p>",
"   <p>",
"    In view of the variable efficacy of current forms of treatment, the clinician has an important role in helping patients adapt to hair loss. Input from other health professionals, such as a clinical psychologist, may be needed. Many patients are helped by involvement in patient support groups. With children, it is often the parents whose reactions must be addressed for the child to adjust to the hair loss. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Explain in detail that although any of the treatments discussed can induce resumption of normal hair growth, none will \"cure\" the disease or prevent recurrence after healing.",
"     </li>",
"     <li>",
"      In the United States, patients can be encouraged to contact the National Alopecia Areata Foundation, a national support group that publishes a newsletter and provides names of local support groups. Address: 14 Mitchell Boulevard, San Rafael, CA 94903; phone: 415-472-3780; email:",
"      <a class=\"external\" href=\"mailto:info@naaf.org\">",
"       info@naaf.org",
"      </a>",
"      ; Web site:",
"      <a class=\"external\" href=\"file://www.naaf.org/\">",
"       www.naaf.org",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/18/7458?source=see_link\">",
"       \"Patient information: Hair loss in men and women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=see_link\">",
"       \"Patient information: Alopecia areata (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alopecia areata is a chronic, relapsing disorder that results in nonscarring hair loss. Not all patients with alopecia areata require treatment; up to 50 percent of patients with limited alopecia areata of less than one year's duration will experience spontaneous regrowth of hair. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cosmetic effects of alopecia areata can cause severe emotional distress; counseling in such patients is essential. (See",
"      <a class=\"local\" href=\"#H550499604\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is relatively little evidence on treatment from well-designed clinical trials. The response to treatment is variable, and some patients may elect not to treat this condition. For patients who desire treatment, we suggest the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that localized scalp alopecia areata be treated with intralesional injections of corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intralesional corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children or adults with limited disease and who have concerns about exposure to intralesional steroids, we suggest treatment with topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Potent topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If intradermal or topical corticosteroid therapy produces an inadequate response, we suggest a trial of topical 5%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      either alone or in combination with continued corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Minoxidil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with extensive alopecia areata, including alopecia totalis, as well as patients with more limited disease who do not respond to the above therapies be treated with topical immunotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients should generally be referred to a dermatologist for such therapy and any additional management. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Topical immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with extensive disease who have failed topical immunotherapy or when such therapy is contraindicated, another option is photochemotherapy. Long-term photochemotherapy should be avoided. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Photochemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic glucocorticoid therapy may induce hair regrowth, and short courses of treatment are occasionally utilized to temporarily halt disease progression in patients with widespread active disease. The potential adverse effects of systemic glucocorticoids make them unfavorable options for long-term management. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Oral glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not desire treatment may benefit from cosmetic interventions. Wigs (particularly in women) and shaving the scalp (in men) may produce an acceptable cosmetic result. Temporary tattooing can be helpful for loss of eyebrows. False eyelashes are available for patients with alopecia of the eyelashes. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Cosmetic approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/1\">",
"      Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012; 166:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/2\">",
"      Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev 2008; :CD004413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/3\">",
"      Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971; 85:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/4\">",
"      Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994; 71:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/5\">",
"      Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010; 62:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/6\">",
"      Campbell LS, Chevalier M, Levy RA, Rhodes A. Hypothalamic-pituitary-adrenal axis suppression related to topical glucocorticoid therapy in a child with psoriatic exfoliative erythroderma. Pediatr Dermatol 2012; 29:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/7\">",
"      Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/8\">",
"      Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/9\">",
"      Ro BI. Alopecia areata in Korea (1982-1994). J Dermatol 1995; 22:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/10\">",
"      Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009; 8:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/11\">",
"      Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000; 136:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/12\">",
"      Kuldeep C, Singhal H, Khare AK, et al. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichology 2011; 3:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/13\">",
"      Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006; 20:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/14\">",
"      Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/15\">",
"      Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998; 39:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/16\">",
"      van der Steen PH, van Baar HM, Perret CM, Happle R. Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/17\">",
"      Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980; 267:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/18\">",
"      Herbst V, Z&ouml;ller M, Kissling S, et al. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006; 16:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/19\">",
"      Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986; 278:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/20\">",
"      Wasy��yszyn T, Koz��owski W, Zabielski SL. Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone. Arch Dermatol Res 2007; 299:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/21\">",
"      Hoffmann R, Wenzel E, Huth A, et al. Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/22\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/23\">",
"      Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/24\">",
"      Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 2005; 5:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/25\">",
"      Dall'oglio F, Nasca MR, Musumeci ML, et al. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat 2005; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/26\">",
"      Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/27\">",
"      Ajith C, Gupta S, Kanwar AJ. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome. J Drugs Dermatol 2006; 5:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/28\">",
"      Kratka J, Goerz G, Vizethum W, Strobel R. Dinitrochlorobenzene: influence on the cytochrome P-450 system and mutagenic effects. Arch Dermatol Res 1979; 266:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/29\">",
"      Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/30\">",
"      Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/31\">",
"      Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J (Clin Res Ed) 1983; 287:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/32\">",
"      Vestey JP, Savin JA. A trial of 1% minoxidil used topically for severe alopecia areata. Acta Derm Venereol 1986; 66:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/33\">",
"      Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987; 16:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/34\">",
"      Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/35\">",
"      Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/36\">",
"      Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/37\">",
"      Claudy AL, Gagnaire D. PUVA treatment of alopecia areata. Arch Dermatol 1983; 119:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/38\">",
"      Lassus A, Eskelinen A, Johansson E. Treatment of alopecia areata with three different PUVA modalities. Photodermatol 1984; 1:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/39\">",
"      Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/40\">",
"      van der Schaar WW, Sillevis Smith JH. An evaluation of PUVA-therapy for alopecia areata. Dermatologica 1984; 168:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/41\">",
"      Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/42\">",
"      Healy E, Rogers S. PUVA treatment for alopecia areata--does it work? A retrospective review of 102 cases. Br J Dermatol 1993; 129:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/43\">",
"      Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/44\">",
"      Winter RJ, Kern F, Blizzard RM. Prednisone therapy for alopecia areata. A follow-up report. Arch Dermatol 1976; 112:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/45\">",
"      Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005; 52:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/46\">",
"      Sladden MJ, Hutchinson PE. Is oral pulsed prednisolone useful in alopecia areata? Critical appraisal of a randomized trial. J Am Acad Dermatol 2005; 53:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/47\">",
"      Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia areata. J Am Acad Dermatol 2002; 46:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/48\">",
"      Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol 2008; 74:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/49\">",
"      Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol 2008; 47:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/50\">",
"      Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/51\">",
"      Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 1990; 22:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/52\">",
"      Phillips MA, Graves JE, Nunley JR. Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol 2005; 53:S252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/53\">",
"      Dyall-Smith D. Alopecia areata in a renal transplant recipient on cyclosporin. Australas J Dermatol 1996; 37:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/54\">",
"      Cerottini JP, Panizzon RG, de Viragh PA. Multifocal alopecia areata during systemic cyclosporine A therapy. Dermatology 1999; 198:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/55\">",
"      Davies MG, Bowers PW. Alopecia areata arising in patients receiving cyclosporin immunosuppression. Br J Dermatol 1995; 132:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/56\">",
"      Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005; 52:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/57\">",
"      Chaves Y, Duarte G, Ben-Said B, et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 2008; 217:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/58\">",
"      Pelivani N, Hassan AS, Braathen LR, et al. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008; 216:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/59\">",
"      Garcia Bartels N, Lee HH, Worm M, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006; 142:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/60\">",
"      Fabre C, Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008; 216:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/61\">",
"      Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004; 140:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/62\">",
"      Tosti A, Pazzaglia M, Starace M, et al. Alopecia areata during treatment with biologic agents. Arch Dermatol 2006; 142:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/63\">",
"      Pan Y, Rao NA. Alopecia areata during etanercept therapy. Ocul Immunol Inflamm 2009; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/64\">",
"      Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005; 141:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/65\">",
"      Strober BE, Menon K, McMichael A, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol 2009; 145:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/66\">",
"      Heffernan MP, Hurley MY, Martin KS, et al. Alefacept for alopecia areata. Arch Dermatol 2005; 141:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/67\">",
"      Bui K, Polisetty S, Gilchrist H, et al. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis 2008; 81:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/68\">",
"      Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006; 55:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/69\">",
"      Kolde G, Meffert H, Rowe E. Successful treatment of alopecia areata with efalizumab. J Eur Acad Dermatol Venereol 2008; 22:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/70\">",
"      Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol 2008; 58:395.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration press announcement. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149561.htm (Accessed on April 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/72\">",
"      Zakaria W, Passeron T, Ostovari N, et al. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol 2004; 51:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/73\">",
"      Nov&aacute;k Z, B&oacute;nis B, Balt&aacute;s E, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B 2002; 67:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/74\">",
"      Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata. Dermatol Surg 2007; 33:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/75\">",
"      Raulin C, G&uuml;ndogan C, Greve B, Gebert S. [Excimer laser therapy of alopecia areata--side-by-side evaluation of a representative area]. J Dtsch Dermatol Ges 2005; 3:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/76\">",
"      Gundogan C, Greve B, Raulin C. Treatment of alopecia areata with the 308-nm xenon chloride excimer laser: case report of two successful treatments with the excimer laser. Lasers Surg Med 2004; 34:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/77\">",
"      Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol 2009; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/78\">",
"      Talpur R, Vu J, Bassett R, et al. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009; 61:592.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/79\">",
"      Ehsani AH, Toosi S, Seirafi H, et al. Capsaicin vs. clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol 2009; 23:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/80\">",
"      Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 2004; 9:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/81\">",
"      Yoo KH, Kim MN, Kim BJ, Kim CW. Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol 2010; 49:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/82\">",
"      Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia 2006; 26:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/83\">",
"      Cho HR, Lew BL, Lew H, Sim WY. Treatment effects of intradermal botulinum toxin type A injection on alopecia areata. Dermatol Surg 2010; 36 Suppl 4:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/84\">",
"      Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004; 51:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/85\">",
"      Herane MI, Urbina F. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol 2004; 18:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/86\">",
"      Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/87\">",
"      Demitsu T, Manabe M, Harima N, et al. Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001; 44:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/88\">",
"      Roseborough I, Lee H, Chwalek J, et al. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009; 60:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/89\">",
"      Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009; 19:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/90\">",
"      Ross EK, Bolduc C, Lui H, Shapiro J. Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol 2005; 53:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/91\">",
"      Coronel-P&eacute;rez IM, Rodr&iacute;guez-Rey EM, Camacho-Mart&iacute;nez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/92\">",
"      Rigopoulos D, Gregoriou S, Korfitis C, et al. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol 2007; 32:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/93\">",
"      Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/94\">",
"      Feldmann KA, Kunte C, Wollenberg A, Wolfe H. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002; 147:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/95\">",
"      Gilhar A, Pillar T, Etzioni A. Topical cyclosporin A in alopecia areata. Acta Derm Venereol 1989; 69:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/96\">",
"      Mauduit G, Lenvers P, Barth&eacute;l&eacute;my H, Thivolet J. [Treatment of severe alopecia areata with topical applications of cyclosporin A]. Ann Dermatol Venereol 1987; 114:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/97\">",
"      Lee JW, Yoo KH, Kim BJ, Kim MN. Photodynamic therapy with methyl 5-aminolevulinate acid combined with microneedle treatment in patients with extensive alopecia areata. Clin Exp Dermatol 2010; 35:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/98\">",
"      Fern&aacute;ndez-Guarino M, Harto A, Garc&iacute;a-Morales I, et al. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol 2008; 33:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/99\">",
"      Bissonnette R, Shapiro J, Zeng H, et al. Topical photodynamic therapy with 5-aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata. Br J Dermatol 2000; 143:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/100\">",
"      Harrison S, Sinclair R. Optimal management of hair loss (alopecia) in children. Am J Clin Dermatol 2003; 4:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/101\">",
"      Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/102\">",
"      Hawit F, Silverberg NB. Alopecia areata in children. Cutis 2008; 82:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/103\">",
"      Alabdulkareem AS, Abahussein AA, Okoro A. Severe alopecia areata treated with systemic corticosteroids. Int J Dermatol 1998; 37:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/104\">",
"      Liakopoulou M, Alifieraki T, Katideniou A, et al. Children with alopecia areata: psychiatric symptomatology and life events. J Am Acad Child Adolesc Psychiatry 1997; 36:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/14/4330/abstract/105\">",
"      Ghanizadeh A. Comorbidity of psychiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. Int J Dermatol 2008; 47:1118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3319 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4330=[""].join("\n");
var outline_f4_14_4330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIRST-LINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - For extensive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potent topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Topical immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SECOND-LINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Minoxidil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anthralin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SYSTEMIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Excimer laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Topical bexarotene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550499787\">",
"      Capsaicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fractional photothermolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1643374672\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      EYELASH ALOPECIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prostaglandin analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      INEFFECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      CONSIDERATIONS FOR THE TREATMENT OF CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      COSMETIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H550499604\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/3319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3319|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/11/24757\" title=\"picture 1\">",
"      Intralesional steroid injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=related_link\">",
"      Patient information: Alopecia areata (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/18/7458?source=related_link\">",
"      Patient information: Hair loss in men and women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_14_4331="Pro-inflammatory treatment options";
var content_f4_14_4331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pro-inflammatory treatment options",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ultrasound-guided percutaneous tenotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical nitric oxide application",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracorporeal shock wave treatment (ESWT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acupuncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autologous blood injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma-rich protein injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulinum injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery (with debridement, arthroscopic drilling)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4331=[""].join("\n");
var outline_f4_14_4331=null;
var title_f4_14_4332="Age related shoulder pain";
var content_f4_14_4332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age-related causes and clinical characteristics of intrinsic shoulder pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Adolescents and young adults",
"       </td>",
"       <td>",
"        Overuse injuries",
"       </td>",
"       <td>",
"        Pain and loss of function associated with a particular athletic activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acromioclavicular sprain",
"       </td>",
"       <td>",
"        Focal pain over acromioclavicular joint; history of trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder instability",
"       </td>",
"       <td>",
"        Minor trauma, high risk of recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Middle-aged and older individuals",
"       </td>",
"       <td>",
"        Rotator cuff tendinopathy or impingement syndrome",
"       </td>",
"       <td>",
"        Pain, difficulty with active abduction and external rotation, pain at night, crepitus may be felt with lifting arm beyond 60&deg; in impingement syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotator cuff tears",
"       </td>",
"       <td>",
"        Pain and inability to actively abduct the arm, passive abduction is preserved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacromial bursitis or inflammatory synovitis",
"       </td>",
"       <td>",
"        Features resemble rotator cuff tendinopathy, may be seen with rheumatoid arthritis, polymyalgia rheumatica, or crystal-induced arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adhesive capsulitis (frozen shoulder)",
"       </td>",
"       <td>",
"        Pain, stiffness, and marked loss of shoulder motion; risk factors include diabetes mellitus and prolonged immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bicipital tendinitis",
"       </td>",
"       <td>",
"        Pain and tenderness anteriorly within the bicipital groove",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoarthritis",
"       </td>",
"       <td>",
"        Associated with damage to the rotator cuff, rheumatoid arthritis, or chondrocalcinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myofascial pain",
"       </td>",
"       <td>",
"        Diffuse soft tissue tenderness in the shoulder region and over the chest wall",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4332=[""].join("\n");
var outline_f4_14_4332=null;
var title_f4_14_4333="Postbronchodilator FEV1";
var content_f4_14_4333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75664%7EPULM%2F52958%7EPULM%2F58723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75664%7EPULM%2F52958%7EPULM%2F58723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postbronchodilator FEV1 as a marker for disability in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        FEV1, percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &gt; lower limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        70 to lower limit of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        60 to 69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        50 to 59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing impairment in patients with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reversibility of FEV1 (percent FEV1",
"change)",
"       </td>",
"       <td class=\"subtitle1\">",
"        or",
"       </td>",
"       <td class=\"subtitle1\">",
"        Airway Hyperresponsiveness",
"(PC20 mg/mL or equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10-19",
"       </td>",
"       <td>",
"        8-&gt;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        0.5-&gt;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"       <td>",
"        &le;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimum medication need in asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Occasional bronchodilator, not daily and/or occasional",
"cromolyn, not daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Daily bronchodilator and/or daily cromolyn and/or daily",
"low-dose inhaled steroid (&lt;800&nbsp;&micro;g beclomethasone or",
"equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Bronchodilator on demand and daily high-dose inhaled",
"steroid (&gt;800&nbsp;&micro;g beclomethasone or equivalent) or",
"occasional course (1-3/yr) systemic steroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Bronchodilator on demand and daily high-dose inhaled",
"steroid (&gt;1000 &micro;g beclomethasone or equivalent) and",
"daily systemic steroid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4333=[""].join("\n");
var outline_f4_14_4333=null;
var title_f4_14_4334="Exposures associated with ILD";
var content_f4_14_4334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80757%7EPULM%2F62236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80757%7EPULM%2F62236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupational and environmental exposures associated with interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhaled inorganic dust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Silicates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silica (\"silicosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asbestos (\"asbestosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Talc (hydrated Mg silicates; \"talcosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kaolin or \"china clay\" (hydrated aluminum silicate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diatomaceous earth (Fuller's earth, aluminum silicate",
"with Fe and Mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nepheline (hard rock containing mixed silicates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aluminum silicates (sericite, sillimanite, zeolite)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Portland cement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mica (principally K and Mg aluminum silicates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beryllium (\"berylliosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Carbon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coal dust (\"coal worker's pneumoconiosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Graphite (\"carbon pneumoconiosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tin (\"stannosis\")&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Aluminum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Powdered aluminum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bauxite (aluminum oxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hard metal dusts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cadmium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Titanium oxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tungsten",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hafnium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Niobium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cobalt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vanadium carbides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron (\"siderosis\", \"arc welder's lung\") Barium (powder",
"of baryte or BaSO4; \"baritosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimony (oxides and alloys)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematite (mixed dusts of iron oxide, silica and",
"silicates; \"siderosilicosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed dusts of silver and iron oxide",
"(\"argyrosiderosis\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CuSO4 neutralized with hydrated lime (Bordeaux mixture;",
"\"vineyard sprayer's lung\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare earths (cerium, scandium, yttrium, lanthanum)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Crystal, RG. Interstitial lung disease. In: Wyngaarden, JB, Smith, LH, Jr, Bennett, JC, (Eds), Cecil Textbook of Medicine, 19th ed, WB Saunders Co, Philadelphia, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupational and environmental exposures associated with interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhaled",
"organic dusts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (hypersensitivity pneumonitis)",
"(Partial list)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\">",
"        Thermophilic fungi (ie,",
"Macropolyspora faeni, Thermactinomyces vulgaris, T. sacchari)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Farmer's lung&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Grain handler's lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Humidifier or air conditioner",
"lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bacteria (ie, Bacillus subtilis, B. cereus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Humidifier lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        True fungi (ie, Aspergillus,",
"Cryptostroma corticale, Aureobasidium pullulans, Penicillium species)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal proteins (eg, bird fancier's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inhaled agents other",
"than inorganic or organic dusts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chemical sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Synthetic - fiber lung (Orlon,",
"polyesters, nylon, acrylic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bakelite worker's lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vinyl chloride, polyvinyl",
"chloride powder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Gases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oxides of nitrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sulfur dioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chlorine gas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methyl isocyanate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Fumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Oxides of",
"zinc, copper, manganese, cadmium, iron, magnesium, nickel, brass,",
"selenium, tin, and antimony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diphenylmethane diisocyanate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trimellitic anhydride toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vapors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thermosetting resins (rubber",
"tire workers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Toluene diisocyanate (TDI -",
"asthmatic reactions prominent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Aerosols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Oils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pyrethrum (a natural insecticide)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Crystal, RG. Interstitial lung disease. In: Wyngaarden, JB, Smith, LH, Jr, Bennett, JC, (Eds), Cecil Textbook of Medicine, 19th ed, WB Saunders Co, Philadelphia, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4334=[""].join("\n");
var outline_f4_14_4334=null;
var title_f4_14_4335="Classic z-plasty";
var content_f4_14_4335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Classic Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The classic Z-plasty consists of three limbs of equal length. The angles between the central limb and each lateral limb are equal and measure 60&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_14_4335=[""].join("\n");
var outline_f4_14_4335=null;
